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ABSTRACT OF THE DISSERTATION 
 
Ubiquitin-proteasome system modulates  
platelet function 
 
By Nilaksh Gupta 
 
Atherothrombotic diseases are responsible for more than 25% of all 
deaths worldwide. Anti-platelet drugs are the mainstay treatment because of the 
direct involvement of platelets in the initiation and propagation of 
thrombosis.  However, the currently available anti-platelet drugs, such as 
antagonists of platelet receptors or of effector systems participating in platelet 
activation,  have their own limitations. A new mode of affecting platelet reactivity 
may prove to offer unique advantages in a host of clinical settings.  
 Proteasome inhibitors are in clinical use to treat hematologic cancers, but 
also reduce thrombosis. Whether the proteasome participates in platelet 
activation or function is opaque since little is known of the proteasome in these 
terminally differentiated cells. Therefore, I investigated the role of proteasome-
mediated proteolysis on platelet function (AIM 1). I find platelets displayed all 
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three primary proteasome protease activities, which MG132 and bortezomib 
(Velcade®) inhibited. Proteasome substrates are marked by ubiquitin, and 
platelets contained a functional ubiquitination system that modified the proteome 
by mono- and poly-ubiquitination. Proteasome inhibition suppressed platelet 
aggregation by low thrombin concentrations and ristocetin-stimulated 
agglutination through the GPIb-IX-V complex. Proteasome inhibitor MG132 
reduced stimulated spreading and clot retraction. The effects of proteasome 
inhibitors were not confined to a single receptor as MG132 and bortezomib 
suppressed thrombin-, ADP-, and LPS-stimulated microparticle shedding. 
Systemic MG132 strongly suppressed formation of occlusive, platelet-rich 
thrombi in FeCl3-damaged carotid arteries. Transfusion of platelets treated ex 
vivo with MG132 and washed prior to transfusion into thrombocytopenic mice 
also reduced carotid artery thrombosis. 
 The inhibition of the proteasome quells the ultimate step of ubiquitin-
mediated protein degradation pathway. Proteasome-mediated degradation is the 
final common step, however, multiple layers of regulated processes are involved 
upstream of this degradative machine that determines whether to target a protein 
for degradation or not. Platelets express a number of deubiquitinases that 
reverse protein ubiquitination, but their potential function in platelets is unstudied. 
So, I investigated the role of deubiquitinase enzymes in modulating platelet 
reactivity (Aim 2).  I show platelets express deubiquitinase activity and specific 
inhibitor of the proteasome-associated deubiquitinases (b-AP15) as well as 
general deubiquitinase inhibitors (PYR41 and PR619) increased mono- and poly-
viii 
 
ubiquitination of platelet proteins. Deubiquitinase inhibition strongly 
suppressed αIIbβ3 activation, degranulation, platelet aggregation and adhesion/ 
spreading in response to diverse platelet agonists. This inhibition also blocked 
downstream signaling from platelet receptors by inhibiting agonist-induced Akt 
phosphorylation and intracellular calcium release. Inhibition of platelet 
deubiquitinase activity strongly suppressed formation of platelet-rich occlusive 
thrombi in FeCl3-damaged murine carotid arteries and prevented in 
vitro thrombus formation on collagen-coated surfaces at high shear rates.  
  Overall, this study uncovers the role of ubiquitin-proteasome system in 
regulating platelet reactivity and thrombosis. 
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CHAPTER I 
Introduction 
1.1 Overview of platelet functions and roles 
 Thrombotic cardiovascular diseases (CVD), predominantly manifested as 
myocardial infarction and ischemic stroke, remain the single most common cause 
of death and disability in the developed world. CVD is responsible for ~30% of all 
deaths worldwide (Alwan 2011), with arterial thrombosis as the main underlying 
cause. In the United States alone, more than 2000 patients die each day as a 
direct result of myocardial infarction and ischemic stroke caused by arterial 
thrombosis (Go, Mozaffarian et al. 2014).  
 The initial trigger for arterial thrombosis, formation of occlusive thrombi 
within the lumen of arteries (Engelmann and Massberg 2013), is the disruption of 
atherosclerotic plaque that exposes its thrombogenic molecules to the arterial 
circulation. When released,  these molecules cause concomitant platelet 
activation and fibrin formation leading to platelet-rich occlusive thrombi (Ruggeri 
2002; Mackman 2008). This occurs often with fatal consequences e.g. thrombotic 
occlusion of coronary artery that results in acute myocardial infarction and 
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occlusive thrombi in cerebral artery that results in ischemic stroke (Michelson 
2010). 
 Platelets are small, disc-shaped anuclear cells that originate from bone 
marrow precursors, megakaryocytes, and circulate in blood as sentinels of 
vascular integrity. Platelet aggregation is a hallmark of hemostasis and a 
contributing factor in pathologic thrombosis (Italiano, Lecine et al. 1999; Hartwig 
and Italiano 2003; Ruggeri and Mendolicchio 2007). In the event of injury to the 
vessel wall, platelets adhere to the exposed subendothelial proteins and 
polymers to undergo rapid aggregation to form the hemostatic plug, the first 
response to stop bleeding. However, platelets cannot distinguish between 
physiological wounds in the vessel lining and pathogenic lesions on diseased 
atherosclerotic vessels. This contributes to atherothrombosis ( thrombosis at 
sites of atherosclerotic plaque disruption), which stops adequate blood supply to 
downstream tissues or organs (Fuster, Badimon et al. 1992; Ruggeri 2000). 
 Owing to the vital role of platelets in athrothrombosis, anti-platelet agents, 
e.g. aspirin and clopidogrel, are widely prescribed for individuals at high risk of 
arterial thrombosis (Michelson 2010). However, the downside is an increased risk 
of bleeding, which limits use of such agents (Fisher and Loscalzo 2011). 
Identifying new therapeutic approaches that prevent thrombosis without 
undermining underlying hemostasis seems imperative, but is restricted by our 
insufficient understanding of molecular events that enhance platelet adhesion, 
and activation and thus prevents identification of new targets to control platelet 
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deposition. Therefore, uncovering of new pathways and advancements in the 
understanding of molecular events that regulate platelet deposition and activation 
in thrombus propagation are sought and are likely to provide new therapeutic 
targets and insight for the improvement of existing anti-platelet agents. 
1.1.1 Role of platelets in hemostasis and thrombosis 
 Blood platelets are all-important for maintaining hemostasis, the cessation 
of bleeding. The critical role of platelets in hemostasis is highlighted by disease 
states that affect platelet number and/or function. For example, disorders 
resulting in abnormally low platelet count, thrombocytopenia, or genetic 
conditions that impair platelet function, such as Bernard-Soulier syndrome (BSS, 
quantitative or qualitative defects in the platelet GPIb-IX-V complex) results in 
increased bleeding (Lanza 2006; Cox, Price et al. 2011). The mammalian 
hemostatic system preserves the integrity of the high pressure circulatory system 
by balancing processes that maintain blood fluidity under physiological conditions 
with those that prevent hemorrhage after penetrating injuries to the vessel wall. 
Maintenance of blood fluidity rests on an intact vessel wall lined by endothelial 
cells (Fig.1.1) that maintains a quiescent inert surface through a series of 
regulatory pathways that prevent platelet activation and keeps the coagulation 
cascade in check (Pinsky, Broekman et al. 2002; Michelson 2010; Lippi, 
Franchini et al. 2011).  
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Figure 1.1 Vascular endothelium keeps platelets quiescent and coagulation 
under check 
 Vascular endothelium keeps platelet quiescent by releasing: Ecto-ADPase 
(CD39) that degrades extracellular adenosine diphosphate (ADP, platelet 
agonist), prostaglandin I2 (PGI2) and nitric oxide (NO
.), both of these 
compounds are potent inhibitors of platelet activation as they stimulate an 
increase in the intracellular levels of cyclic adenosine monophosphate (cAMP) 
and cyclic guanosine monophosphate (cGMP), respectively. Vascular 
endothelium keeps coagulation under check by releasing: Thrombomodulin 
(TM), which via activated protein C (APC), inhibits factor (F) Va and FVIIIa and 
tissue factor pathway inhibitor (TFPI), which inhibits FXa and the TF/FVIIa 
complex. Heparin acts as a cofactor for anti-thrombin, which inhibits thrombin, 
FXa, FXIa and FIXa [ figure modified from (Otsuka, Finn et al. 2012) ].  
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 However, disruption or fissuring of an unstable atherosclerotic plaque 
compromises endothelial integrity  and triggers instant platelet recruitment and 
activation to the exposed thrombogenic subendothelial matrix proteins (Fig.1.2) 
(Schulz and Massberg 2012).  
 Recruitment of platelets at the site of the ruptured plaque is an immediate 
response. This involves interactions between platelet-cell surface receptors and 
exposed subendothelial matrix proteins including fibrillar collagen (type I and III) 
and von Willebrand factor (VWF) (Savage, Almus-Jacobs et al. 1998; Massberg, 
Gawaz et al. 2003; Denis and Wagner 2007). Platelet recruitment via individual 
receptor-ligand interactions depends on the extent of vascular damage, as well 
as prevailing rheological conditions. Importantly, shear rates up to 10,000 s-1 
have been observed in the coronary artery occluded by 50% and even up to 
50,000 s-1 in severe stenosis (Strony, Beaudoin et al. 1993; Mailhac, Badimon et 
al. 1994) VS normal shear flow. 
 Under conditions of rapid blood flow, a feature of arterioles and stenotic 
arteries, VWF recruits circulating platelets by reversible binding of its A1 domain 
with multiple GPIb-IX-V receptors. Platelet GPIb-IX-V is essential for the initial 
recruitment of platelets on the vascular lesion under high shear conditions 
(Savage, Saldivar et al. 1996; Goto, Ikeda et al. 1998; Ruggeri 2001; Ruggeri 
and Mendolicchio 2007). The VWF-GPIbα bond displays rapid on-off rates that 
facilitates platelet translocation to the vessel wall, but it does not support stable 
adhesion and requires the contribution of additional interactions between 
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platelets and other matrix macromolecules (Savage, Almus-Jacobs et al. 1998). 
Stable platelet adhesion occurs through engagement of platelet glycoprotein 
VI (gpVI) to collagen (Nieswandt, Brakebusch et al. 2001; Furie and Furie 2006) 
that triggers downstream signaling leading to platelet activation.  
 This is critical for subsequent platelet activation as platelet stimulation 
upon engagement with gpVI causes synthesis and release of secondary platelet 
agonists, most notably thromboxane A2 (TxA2) and ADP, as well as locally 
generated thrombin, further amplifying platelet activation in an autocrine or 
paracrine fashion by stimulating their respective receptors on platelets (Share 
1976; Offermanns 2006). Inside-out signaling from both gpVI and GPIb-IX-V 
receptors induces a change in the activation status of β1 integrins {α2β1 [a 
Collagen receptor], α5β1 [a fibronectin receptor] (Beumer, MJ et al. 1994), and 
α6β1 [a laminin receptor] (Ruggeri 2009)}  and β3 integrin,  αIIbβ3 (binding VWF, 
fibrinogen and fibronectin), from low affinity ligand binding states to high affinity 
states (Shattil, Kim et al. 2010). Of all the integrins, αIIbβ3 is the dominant 
integrin present on platelet surface, and high affinity adhesive interactions 
between αIIbβ3 and adhesive proteins VWF, fibrinogen and fibronectin are 
central to the irreversible platelet activation and thrombus propagation at the site 
of ruptured plaque (Savage, Saldivar et al. 1996; Vinogradova, Velyvis et al. 
2002). 
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Figure 1.2 Mechanism of platelet recruitment following plaque 
rupture 
Plaque rupture exposes subendothelial proteins VWF and Collagen. Platelets 
constitutively express receptors for these protein and are recruited to the 
endothelium from the circulation, initially via GPIbα-VWF interactions (tethering). 
Once slowed, platelets can bind collagen via its gpVI receptor and downstream 
signaling initiated from this interaction activate platelets (activation). Platelet 
activation leads to integrin (αIIbβ3 and α2β1) activation, from inside-out signaling, 
leading to irreversible platelet activation and firm adhesion (adhesion). Figure 
adapted from (Schulz and Massberg 2012).    
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1.1.1.1 Blood coagulation and thrombin generation 
 An important function of activated platelets is localization of subsequent 
pro-coagulant events to the site of ruptured plaque. Platelet activation leads to 
the rapid exposure of the membrane phospholipid phosphatidylserine (PS) from 
inner membrane leaflet to platelet surface, which provides the anionic surface to 
support the assembly of coagulation complexes on the platelet plasma 
membrane. This is critical for localized thrombin generation and fibrin formation 
(Jackson 2011). Thrombin is one of the most potent endogenous platelet 
agonists, and plays a seminal role in thrombus formation under all rheological 
conditions (Kahn, Zheng et al. 1998). Thrombin’s effect on human platelets is 
mediated by surface G protein-coupled protease-activated receptor (PAR) 1 and 
4 (Coughlin 1993; Coughlin 1999; Coughlin 2005). Thrombin-induced platelet 
activation and fibrin generation is crucial for thrombus growth and stability, and 
hence  the drugs that inhibit thrombin generation or thrombin-induced platelet 
activation, inhibit atherothrombosis (Michelson 2010).   
1.1.1.2 Spatial and temporal heterogeneity within growing thrombus in 
vivo-  a revised model of thrombus development 
 Recent studies using high resolution intravital confocal microscopy, 
genetically engineered mice, and flow chambers demonstrate that the above 
description of occlusive thrombi formation may be more complicated than 
previously anticipated. There studies also provide sufficient evidence of spatial 
and temporal heterogeneity within the growing thrombi (Fig.1.3)   
 
9 
 
 
 
 
 
 
 
 
 
Figure 1.3 Spatial and temporal heterogeniety of thrombus development  
Plaque rupture leads to the capture of platelets from circulation on to 
thrombogenic endothelium matrix proteins and polymers. Subsequent platelet 
activation via ADP and TxA2 leads to the formation of highly active platelet core. 
Shear flow gradient generated at the site, due to narrowing of the lumen, causes 
platelet tethering and formation of outer shell, composed mainly of discoid and 
ready to be activated platelets. Adapted from (McFadyen and Jackson 2013). 
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 (Nesbitt, Westein et al. 2009; Stalker, Traxler et al. 2013). Capturing thrombus 
development in real-time reveals the heterogeneity in the growing thrombus, 
which appears to have an inner core containing activated platelets and an outer 
shell comprising of poorly activated discoid platelets. Elegant studies of blood 
circulation in vivo and in flow chambers reveal that the growing platelet 
aggregates were sensitive to prevailing rheological conditions i.e. to the flow 
gradient established around the growing thrombus. This flow gradient results in 
the recruitment of circulating discoid platelets to the growing thrombi through the 
extension of their membrane, called tethers. These unactivated platelets in 
thrombi are ready for activation dependent changes leading to thrombus 
stabilization. (Nesbitt, Westein et al. 2009; Stalker, Traxler et al. 2013).  
  Importantly, accumulation of discoid platelets on developing thrombi by 
shear gradients is not impeded by  widely used anti-platelet agents aspirin and 
clopidogrel or thrombin inhibitors (Nesbitt, Westein et al. 2009).  Thus, improved 
understanding of interaction of local conditions at sites of injury or plaque rupture 
with the platelet signaling network offers a new context and rational into how 
future anti-thrombotic drugs should be designed. 
1.1.2 Platelet morphology and ultrastructure 
1.1.2.1 Plasma membrane (PM) and open canalicular system (OCS)  
 Resting platelets are discoid, roughly 2-3 µm in diameter and their number 
range from 150,000 to 450,000 cells/µL in human blood. About two-third of the 
platelets exist in the circulation and the remaining cells are sequestered in the 
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spleen. Platelets have a life span of ~8-10 days (Hartwig and Italiano 2003; Thon 
and Italiano 2012).  
 The platelet plasma membrane is a typical phospholipid bilayer, but also 
contains an extensive series of complex indentations called the open canalicular 
system (OCS) (Fig.1.4) (Behnke 1970; Frojmovic, Wong et al. 1992). The OCS is 
a surface connected tubular system that connects the cytosol with the 
surrounding medium and facilitates the quick release of secreted substances to 
the extracellular environment (White and Clawson 1980; White and Krumwiede 
1987). The OCS also constitutes an extensive membrane reservoir that upon 
activation results in increased plasma membrane surface area that facilitates 
fillopodia formation and platelet spreading (Thon and Italiano 2012). Embedded 
in the platelet plasma membrane are numerous glycoprotein receptors (GP) and 
integrins that are involved in the initial adhesion of platelets to the subendothelial 
matrix and formation of a hemostatic plug (Phillips and Agin 1977; Kunicki 1989). 
The negatively charged plasma membrane phospholipids (e.g. 
phosphatidylserine and phosphatidylinositol) present in the inner leaflet of resting 
platelets, are translocated and exposed on the platelet surface upon activation to 
provide the surface for binding of proteins involved in coagulation (Heemskerk, 
Bevers et al. 2002). The phosphatidylserine exposure on the surface of activated 
platelets is crucial for normal hemostasis and this is evident from a rare bleeding 
disorder, Scott syndrome, where the patients have reduced  
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phosphatidylserine exposure on surface and are unable to make microparticles 
upon platelet activation (Toti, Satta et al. 1996; Heemskerk, Bevers et al. 2002).  
1.1.2.1.1 Platelet derived microparticles (PMPs) 
 PMPs  are small  (0.1-1.0 µm in diameter) phospholipid vesicles, which 
are shed from the cell membrane following platelet activation. PMPs are highly 
pro-thrombotic because their surface contains exposed phosphatidylserine, 
which provides the ideal catalytic surface that greatly expedites coagulation 
(Sandberg, Bode et al. 1985; Sims, Faioni et al. 1988). Elevated numbers of 
circulating PMPs  have been detected during several diverse pathophysiological 
processes such as acute myocardial infarction, peripheral artery disease, 
cerebral malaria, rheumatoid arthritis, diabetes, multiple sclerosis, sepsis, and 
ischemic stroke (Soriano, Jy et al. 2005; Faille, Combes et al. 2009; Boilard, 
Nigrovic et al. 2010; Lannan, Phipps et al. 2014).
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Figure 1.4 Platelet ultrastructure 
The role of platelet granules (alpha and dense granules and lysosomes), OCS, 
dense tubular system and cytoskeleton is explained in the text. Mitochondria are 
the energy source. Resting platelets fulfill their energy requirements by oxidative 
phosphorylation to maintain platelet function and membrane asymmetry. 
Glycogen provides the energy for platelet reactions. Platelet glycocalyx is very 
dynamic and is covered by glycoprotein receptors. Source 
(http://www.studyblue.com/notes/note/n/platelets/deck/2298597).  
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1.1.2.2 Dense Tubular System (DTS) 
 Another membranous system present in platelets is termed as the DTS 
that is a closed-channel network of residual smooth endoplasmic reticulum 
(White 1972). The DTS sequesters ionized calcium and probably also a major 
site of TxA2 and prostaglandin synthesis (Gerrard, White et al. 1976; Gerrard, 
White et al. 1978). The release of intracellular calcium from DTS upon platelet 
activation contributes to platelet degranulation, cytoskeletal reorganization and 
redistribution of αIIbβ3. 
1.1.2.3 Platelet Cytoskeleton 
 Platelets undergo rapid shape change, spreading, secretion and/or 
aggregation upon activation. This transformation in stimulated platelets is largely 
achieved  by rapid cytoskeletal rearrangements within the platelet (Hartwig 
2006). The platelet cytoskeleton consists of a marginal band consisting of a 
microtubule coil, a cytoplasmic actin network, and cytoskeletal rim. Together 
these structures support the platelet plasma membrane and confer shape to both 
resting and activated platelets. This inherent capacity of platelets to rapidly 
reorganize its cytoskeleton allows them to seal the leaks in the vasculature under 
shear conditions (Hartwig 2006; Thon and Italiano 2012).  
 The marginal band lies beneath the plasma membrane and confers the 
discoid shape to the resting platelet. Microtubule disassembly with drugs such as 
nocodazole or colchicine or depolymerization induced by chilling at 4ºC, cause 
15 
 
platelets to lose their discoid shape and become round (White and Krivit 1967; 
White 1968; Hartwig 2006).  
 The cytoskeletal rim is composed of actin, spectrin, talin, vinculin and actin 
cross-linking proteins filamin and α-actinin (Fox 2001; Hartwig 2006). Filamins 
are large cytoplasmic proteins that give mechanical stability to cells by cross-
linking actin into dynamic 3-dimensional structures (Pudas, Kiema et al. 2005). 
There are three filamin isoforms: filamin A (FlnA), filamin B (FlnB) and filamin C 
(FlnC), but platelets only express FlnA and FlnB. FlnA is an elongated 280-kDa 
dimeric protein that self associates and is expressed ~10 fold in excess to FlnB 
(Falet, Pollitt et al. 2010). Structurally, FlnA contains an actin-binding domain 
(ABD) at the N-terminus, followed by 24 compact immunoglobulin-like repeats of 
90–100 amino acids, and a C-terminal domain (Fig. 1.5). Repeat 24 mediates 
dimerization (Pudas, Kiema et al. 2005) (Nakamura, Pudas et al. 2006). Two 
unstructured hinge regions separate FlnA repeat domains into rod 1 (repeats 1–
15), rod 2 (repeats 16–23), and the self-association domain. Rod 1 that binds 
actin filaments is elongated and linear, but Rod 2 that contains most binding sites 
for FlnA partners, has a more compact structure. FlnA has over 70 binding 
partners and in platelets FlnA links the GPIb-IX-V receptor complex to F-actin. 
More than 90% of FlnA in platelets is in complex with GPIbα (Nakamura, Pudas 
et al. 2006; Falet, Pollitt et al. 2010). This interaction has been mapped to FlnA 
repeat 17 and aa 563–571 (FRSSLFLWV) in the cytoplasmic tail of GPIbα 
(Nakamura, Pudas et al. 2006).  
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Figure 1.5 Structure of Filamin A (FlnA) 
FlnA structure showing N-terminal actin-binding domain (ABD); 24 compact 
immunoglobulin-like repeats; C-terminal dimerization domain;  predicted calpain 
cut site and proteasome-tryptic cut site; and GPIbα binding site at repeat 17. 
Adapted from (Gupta, Li et al. 2014). 
 
 
 
 
 
GPIbα binding site 
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The FlnA-GPIbα interaction in platelets is critical for anchoring the GPIb-IX-V 
receptor complex to the membrane skeleton as well as for maintaining cell 
adhesion under high shear (Cranmer, Ashworth et al. 2011). This FlnA-GPIbα 
interaction is also vital for formation and release of discoid platelets from 
megakaryocytes, the platelet precursor cells (Jurak Begonja, Hoffmeister et al. 
2011). 
 The cytoplasmic actin network comprised of actin (which accounts for 
~20% of total platelet protein mass) filaments and associated proteins (Oda, 
Daley et al. 1992). In unstimulated platelets, 40% of the actin is filamentous F-
actin, and the rest is globular monomeric G-actin.  Upon stimulation, the actin 
filaments in platelets are severed and resulting smaller fragments are used as 
the focal point for new, longer actin filaments. This leads to an increase in the F-
actin proportion to ~70% to 80% (Kovacsovics and Hartwig 1996). Myosin IIa, the 
contractile protein, is rapidly phosphorylated by myosin light chain kinase (MLCK) 
following platelet activation and becomes associated with F-actin (Fox and 
Phillips 1982) and forms filaments that are anchored to the platelet plasma 
membrane by attachment (via FlnA) to the GPIb-IX-V complex (Kovacsovics and 
Hartwig 1996). Myosin IIa phosphorylation following platelet activation is 
essential for clot retraction and granule centralization (Cohen, Gerrard et al. 
1982; Stark, Golla et al. 1991). 
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1.1.2.4 Platelet Secretary Granules 
 Platelets contain secretary granules packed with preformed bioactive 
molecules, released upon platelet activation, that are essential for normal platelet 
function. Platelets have three distinct secretary granules; alpha granules, dense 
granules and lysosomes, each with different morphologies, molecular content, 
and kinetics of exocytosis (Flaumenhaft 2003; Coppinger, Cagney et al. 2004).  
 The  α-granules are the largest and most abundant platelet granule, 
outnumbering dense granules by ~10-fold (Koseoglu and Flaumenhaft 2013). 
These granules contain pro-coagulant proteins (fibrinogen, VWF, platelet factor 
4), coagulation factor V, glycoprotein CD62P (P-selectin), CD36, growth-
promoting factors and mitogens [platelet-derived growth factor (PDGF), 
thrombospondin, vascular endothelial growth factor (VEGF), transforming growth 
factor β (TGFβ) etc. (Coppinger, Cagney et al. 2004).  
 Dense granules are the smallest platelet granules and humans platelets 
contain ~3-9 dense granules/platelet (White 1969). They house a variety of 
hemostatically active molecules such as calcium, magnesium, serotonin and 
ADP/ATP (ratio 3/2), that are released upon platelet activation to recruit 
additional platelet at sites of vascular injury (Rendu and Brohard-Bohn 2001; 
King and Reed 2002). Transport of serotonin in platelet dense granules is 
essential for liver regeneration (Lesurtel, Graf et al. 2006). 
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 P-selectin (from α-granules) expression on the surface of stimulated 
platelets and ATP release from dense granules are frequently used markers to 
assess the activation state of platelets in vitro. 
 Lysosomes are formed during megakaryocyte maturation earlier than α-
granules. Platelets have few primary and secondary lysosomes and their size lies 
between dense and α-granules (Menard, Meyers et al. 1990). They contain 
hydrolases (such as cathepsins D and E) elastase and membrane proteins 
LAMP-1, -2 and -3 (Bentfeld-Barker and Bainton 1982; Israels, McMillan et al. 
1996; McNicol and Israels 1999).   
1.1.3 Platelet Receptors  
 Platelets express a great number of receptors (Fig. 1.6), respond to  many 
agonists,  and trigger a surfeit of signaling pathways. Importantly, these receptors 
are not merely redundant as  genetic defects or pharmacological inhibition of any 
of these molecules has a significant effect on platelet function e.g. patients 
suffering from BSS (with defects in the GP1b-X-V complex) have bleeding 
disorder or pharmacologic inhibition of αIIbβ3 inhibits platelet aggregation. In the 
next section, I will focus on the receptors involved in my research work. 
1.1.3.1 Adhesive receptors  
1.1.3.1.1 Integrins 
 Integrins are a broadly distributed family of heterodimeric (α and β 
subunits) cell surface adhesion receptors that occupy ~ 50% of surface area of 
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an activated platelet. A hallmark of integrins is their ability to cycle from a low 
affinity ligand binding state (resting platelets) to a high affinity ligand binding state 
(activated platelets), a property that is of particular importance to blood cells such 
as platelets (Carman and Springer 2003).  
 Platelets express two major integrin β subunits, β1 and β3 and five α-
subunits. The β1-integrins present in platelets are α2β1, and α6β1(Hynes 2002; 
Kasirer-Friede, Kahn et al. 2007). Of all the integrins, αIIbβ3 is the dominant 
integrin on platelet surface and plays a prominent role in platelet aggregation by 
binding plasma fibrinogen. Approximately 40,000-80,000 copies are present per 
platelet (Kauskot and Hoylaerts 2012). Upon platelet activation through ADP, 
thrombin, TxA2 or collagen, αIIbβ3 undergoes conformational change to a high 
affinity state.  This process is termed inside-out signaling (Shattil and Newman 
2004). The signaling axis for αIIbβ3 activation involves Rap1, RIAM, talin and 
kindlin-3 (Banno and Ginsberg 2008; Metcalf, Moore et al. 2010). Fibrinogen 
binding to the activated αIIbβ3 relays outside-in signaling via the signaling 
proteins FAK, Pyk2, SFKs (Src, Fyn and Yes), PI3Kβ, or SHIP1 to the actin-
myosin cytoskeleton and all of this is important for thrombus stability and clot 
retraction (Shattil and Newman 2004; Suzuki-Inoue, Hughes et al. 2007; 
Gratacap, Guillermet-Guibert et al. 2011).   
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Figure 1.6 Platelet receptors.  
The initial recruitment of platelets to injured endothelium is mediated by the 
adhesion receptors; GPIb-IX-V binds the VWF (green balls), α2β1 and gpVI 
binding to collagen (white and gray strands), and αIIbβ3 binds fibrinogen (blue 
bar) to form platelet aggregates. Secondary platelet activation is largely driven by 
cell surface G- protein coupled receptors, most notably the ADP receptors P2Y1 
and P2Y12, ATP receptor P2X1,  thrombin  receptors PAR1 and PAR4, and the 
TxA2  receptor, TPα. Adapted from (http://platelets.se/platelets/) 
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 Since the αIIbβ3 receptor is absolutely essential for irreversible platelet 
activation and thrombus propagation in vivo (Savage, Saldivar et al. 1996; 
Vinogradova, Velyvis et al. 2002), pharmacologic inhibitors of this receptor had 
been developed and are in clinical use. Three inhibitors, abciximab, eptifibatide 
and tirofiban are FDA approved for percutaneous coronory intervention (PCI, 
(abciximab and eptifibatide) and acute coronory syndrome (ACS, eptifibatide and 
tirofiban). The major limitation of these drugs is increased incidence of bleeding, 
which restricts their use to only high risk patients who have not been pretreated 
with P2Y12 receptor antagonists (Michelson 2010; Muniz-Lozano, Rollini et al. 
2013). 
1.1.3.1.2 Glycoprotein Ib-IX-V 
 The  GPIb-IX-V receptor complex is crucial for the initial adhesion of 
circulating platelets to the injured vascular surface via its interaction with its 
ligand VWF at high shear rates (Savage, Saldivar et al. 1996; Goto, Ikeda et al. 
1998; Ruggeri 2001; Ruggeri and Mendolicchio 2007). This receptor complex is 
constitutively expressed on platelet surface with the density of about 25000 
copies per platelet (Modderman, Admiraal et al. 1992) and consists of 4 distinct 
non-covalently attached subunits namely, glycoprotein Ibα (GPIbα), glycoprotein 
Ibβ (GPIbβ), glycoprotein IX (GPIX), and glycoprotein V (GPV)  in the ratio 
2:2:2:1 (Ware 1998; Kauskot and Hoylaerts 2012). The N-terminal extracellular 
region of GPIbα contains the binding sites for VWF, P-selectin, Mac-1 (integrin 
α2βM), coagulation factors XI (Baglia, Badellino et al. 2002) and FXII (Bradford, 
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Pixley et al. 2000), high-molecular-weight kininogen (Lanza 2006) and thrombin 
(De Marco, Mazzucato et al. 1994; Adam, Bouton et al. 2003). The intracellular 
cytoplasmic domain of GPIbα is linked to FlnA and this interaction tethers the 
GPIb-IX-V receptor complex to the platelet cytoskeleton, maintaining the 
cytoskeletal architecture of resting platelets and those adhering in vessels at high 
shear rates (Cranmer, Ashworth et al. 2011).  
 In the absence of any vascular trauma, plasma VWF does not normally 
bind to platelets, since the GPIbα binding VWF-A1 domain is inaccessible 
(Miyata, Goto et al. 1996). However, damage to vessel wall exposes 
subendothelial collagen, enabling VWF to bind collagen through its A3 domain. 
This and/or  high shear stress induces conformational change in VWF, exposing 
the otherwise cryptic binding site on VWF-A1 for the GPIb-IX-V complex 
(Siedlecki, Lestini et al. 1996). The snake venom peptide botrocetin (Read, Smith 
et al. 1989) or the antibiotic ristocetin (Scott, Montgomery et al. 1991) can also 
be used to induce vWF-GPIbα interaction in vitro.  
 GPIbα, which is primarily regarded as the VWF receptor, also contains a 
high affinity binding site for thrombin that contributes to platelet activation at low 
thrombin concentrations and plays a significant role in the generation of platelet 
microparticles and their procoagulant activity (Harmon and Jamieson 1986; 
Dormann, Clemetson et al. 2000). The importance of thrombin binding to GPIbα 
became evident after the observation that patients with a rare autosomal 
recessive condition called BSS (quantitative or qualitative defects in the platelet 
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GPIb-IX-V complex) (Lanza 2006; Cox, Price et al. 2011), showed reduced 
responsiveness to thrombin (Ganguly 1977; Jamieson and Okumura 1978). 
GPIbα also increases the rate of protease-activated receptor 1 (PAR1, discussed 
later) hydrolysis by 5 fold, indicating that GPIbα may act as a cofactor that 
facilitates PAR 1 cleavage (De Candia, Hall et al. 2001). A specific mutation that 
only blocked thrombin-GPIbα interaction reduced the ability of murine platelets to 
form thrombi, suggesting this interaction is essential for thrombosis. Importantly, 
blocking thrombin-GPIbα interaction in vivo had no effect on bleeding time, 
making this interaction a suitable therapeutic target  (Guerrero, Shafirstein et al. 
2008).  
1.1.3.1.3 Collagen Receptors 
 The subendothelial matrix protein collagen is a key initiator of platelet 
responses by not only serving as a substrate for platelet adhesion, but also by 
acting as a potent platelet agonist. Two major direct receptors have been 
implicated in the platelet responses to collagen:  α2β1 and glycoprotein VI (gpVI).  
α2β1, a member of the integrin family, serves primarily to anchor platelets to 
subendothelial collagen exposed after vascular injury. Basically, gpVI-collagen 
interaction is weak, but provides a potent stimulus for intracellular signaling. As a 
result of this signaling, α2β1 is induced to bind collagen with high affinity thereby 
contributing to firm interaction between platelets and subendothelial collagen 
(Jung and Moroi 1998; Polanowska-Grabowska, Simon et al. 1999; Nieswandt, 
Brakebusch et al. 2001; Chen and Kahn 2003; Horii, Kahn et al. 2006).  
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 GPVI is predominantly a signaling receptor that belongs to the 
immunoglobulin (Ig) superfamily whose expression is restricted to platelets and 
megakaryocytes.  Approximately, 4000–6000 copies of gpVI are present/platelet 
(Clemetson, Polgar et al. 1999; Jandrot-Perrus, Busfield et al. 2000). GPVI exists 
as a single transmembrane receptor and its ability to generate signals rests on 
the interaction between its  transmembrane domain and immunoreceptor 
tyrosine-based activation domain (ITAM)-containing Fc receptor γ chain (FcRγ) 
(Kahn 2004). This gpVI- FcRγ chain interaction is critical for receptor stabilization 
and downstream signaling as mice deﬁcient in FcRγ are unresponsive to 
collagen in part due to loss of signaling and in part because of their failure to 
express the receptor on the surface of their platelets (Poole, Gibbins et al. 1997; 
Tsuji, Ezumi et al. 1997; Kato, Kanaji et al. 2003). Collagen stimulation induces 
cross-linking of the gpVI- FcRγ chain complex resulting in sequential activation of 
Src and Syk family tyrosine kinases which further activates phosphatidylinositol 
3-kinase β (PI3Kβ). This leads to phospholipase C γ2 (PLCγ2) activation, where 
PIP2 hydrolysis increases intracellular calcium and induces diacylglycerol (DAG) 
production. Both of these events are crucial for αIIbβ3 activation and subsequent 
platelet aggregation (Watson, Auger et al. 2005). 
 Platelets from humans with gpVI deficiency are nonresponsive to collagen 
(Sugiyama, Okuma et al. 1987; Kahn 2004) and gpVI polymorphisms are 
associated with increased risk of myocardial infarction (Yee and Bray 2004). 
Interestingly, inhibition or loss of gpVI prevented arterial thrombosis in animal 
models, but only mildly perturbed the normal hemostasis in both mice and 
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humans (Kahn 2004), making gpVI a suitable therapeutic target. A soluble gpVI-
Fc fusion protein (Revacept) that blocks the gpVI-binding sites on exposed 
collagen suppresses murine arterial thrombosis without a bleeding phenotype. 
Revacept is currently being tested in phase II trials (Ungerer, Rosport et al. 
2011).  
1.1.3.2 G- Protein Coupled Receptors 
1.1.3.2.1 Thrombin Receptors 
 Thrombin’s effect on human platelets is mainly mediated by surface 
GPCRs called protease-activated receptor (PAR) 1 and 4 and GP1bα (described 
above). 
1.1.3.2.1.1 PARs 
 PAR1 was the first identified protease-activated receptor and out of four 
known PARs, human platelets express PAR1 and PAR4, whereas, murine 
platelets express only PAR3 and PAR4. (Coughlin 1993; Kahn, Zheng et al. 
1998; Coughlin 1999; Coughlin 2005). PAR1 is a prototype of this family, and 
accounts for the majority of cellular responses to thrombin. PAR1 is activated 
through proteolytic cleavage of its extracellular N-terminal, carboxyl to the R41 
residue, to yield the tethered ligand sequence S42FLLRN. This tethered ligand 
can bind intra-molecularly to the cleaved PAR1 receptor to initiate signaling (Vu, 
Hung et al. 1991; Macfarlane, Seatter et al. 2001). Proteolytic cleavage of the 
extracellular N-terminus of PAR4 yields the tethered ligand sequence GYPGQV. 
PAR1 or PAR4 activation can also be triggered by short synthetic peptides, 
27 
 
SFLLRN (PAR1) or AYPGKF (PAR4), mimicking the sequence of tethered ligand 
without any receptor cleavage (Vu, Hung et al. 1991; Scarborough, Naughton et 
al. 1992; Vassallo, Kieber-Emmons et al. 1992).  
 Among the PARs of human platelets, PAR1 is the high affinity thrombin 
receptor, in contrast to PAR4 that is a low affinity thrombin receptor that needs 
higher concentration of thrombin for activation. Furthermore, both PAR1 and 
PAR4 exhibit different kinetics of calcium mobilization: PAR1 activation induces a 
rapid increase in intracellular calcium, on the other hand, PAR4 triggers a more 
prolonged and sustained increase in intracellular calcium (Covic, Gresser et al. 
2000; Jacques and Kuliopulos 2003; Coughlin 2005). Stimulation of PAR1 and 
PAR4 with its ligand activates a complex array of downstream pathways by 
coupling directly with G proteins; Gαq, Gαi and Gα12/13. Stimulation of the Gαq 
pathway activates phospholipase Cβ (PLCβ) that hydrolyzes the membrane- 
bound phosphatidylinositol 4,5- bisphosphate (PIP2) substrate into DAG and the 
secondary messenger inositol 1,4,5- triphosphate (IP3). IP3 binds to its receptors 
on the dense tubular system leading to an increase in cytosolic calcium 
concentration, while DAG activates protein kinase C (PKC). This signaling 
pathway initiates calcium-dependent cytoskeletal reorganization, leading to 
platelet shape change, aggregation and degranulation (Gabbeta, Yang et al. 
1997; Offermanns, Toombs et al. 1997).  Stimulation of  the Gα12/13 pathway 
activates Rho, RhoA, and p160ROCK pathways that lead to calcium-independent 
platelet shape change and dense granule release (Paul, Daniel et al. 1999).   
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 PAR1 plays a crucial role in platelet activation and thrombus stabilization 
and in accordance with this PAR1 antagonist, Vorapaxar and Atopaxar, were 
developed and clinical trials have been performed. Table 1.1 summarizes the 
clinical trial status as well as limitations of PAR1 antagonists. 
1.1.3.2.1.2 ADP Receptors 
 Adenosine 5’-diphosphate (ADP) is a physiologic, endogenous platelet 
agonist critical for normal hemostasis and thrombosis. ADP is stored in platelet 
dense granules and is secreted upon platelet activation. Shear stress can also 
induce ADP release from erythrocytes. ADP amplifies platelet activation initiated 
by other agonists, and is vital for maximal platelet aggregation under high shear 
conditions. ADP acts in an autocrine/paracrine manner and binds two different G- 
protein coupled purinergic receptors, P2Y1 and P2Y12 (Oury, Toth-Zsamboki et al. 
2006). P2Y1, couples to Gαq and activates phospholipase Cβ (PLCβ) that triggers 
mobilization of intra-platelet calcium stores. This calcium flux initiates cytoskeletal 
reorganization leading to platelet shape change and aggregation (Ebbeling, 
Robertson et al. 1992; Jardin, Lopez et al. 2008). P2Y12 is a Gαi-coupled receptor 
that inhibits adenylate cyclase (AC) leading to reduction in the intracellular levels 
of the signaling messenger cyclic adenosine monophosphate (cAMP), while Gβγ 
dimers activate phosphoinositide 3-kinase (PI3Kβ/γ). This regulates platelet 
aggregation via actin cytoskeleton-dependent integrin αIIbβ3 activation (Chen, 
De et al. 2004). Continuous signaling through P2Y12 is critical for persistent αIIbβ3 
activation and thrombus stability under shear flow conditions (Cosemans, Munnix 
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et al. 2006). In accordance with their important role in initial platelet activation 
and thrombus formation, the ADP receptor (P2Y12) is the pharmacological target 
of many anti-platelet drugs in clinical practice. Table 1.1 gives the list of drugs 
targeting this receptor and their potential limitations. 
1.1.4 Current anti-platelet therapies and their limitations 
 An exaggerated platelet response at sites of atherosclerotic plaque 
disruption leads to athrothrombosis, the underlying cause of myocardial infarction 
and ischemic stroke. It is no wonder then, that platelets are the main targets for 
therapeutic intervention. However, despite improvements in our understanding of 
the mechanisms contributing to thrombus formation and the presence of several 
anti-platelet therapies, athrothrombosis is still the leading   cause   of   morbidity 
and mortality in the developed world (Alwan 2011; Jackson 2011).  
 All the existing anti-platelet agents work by inhibiting signaling 
mechanisms that amplify platelet activation (ADP and TxA2 secretion),  platelet 
aggregation (αIIbβ3), or phosphodiestrases (PDE) that degrade cyclic 
nucleotides (cAMP and cGMP) (Choi and Kermode 2011). Anti-platelet drugs 
aspirin (inhibits TxA2) and clopidogrel (P2Y12 receptor antagonist) alone have 
limited protection against arterial  thrombosis (Awtry and Loscalzo 2000; Savi, 
Pereillo et al. 2000; Pereillo, Maftouh et al. 2002), but dual therapy with both 
drugs is the gold-standard anti-platelet therapy (Anderson, Adams et al. 2007; 
Anderson, Adams et al. 2013).   
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 While  the  combined  administration  of  both  drugs  reduced vascular 
events (myocardial infarction or ischemic stroke) by ~ 25% in patients with CVD 
(Choi and Kermode 2011), the relative impact of this reduction is  marginal   due   
to the associated increased incidence of severe bleeding (Chen, Jiang et al. 
2005; Choi and Kermode 2011).  In fact, this is an inherent weakness with 
most anti-platelet drugs in clinical practice. Table 1 summarizes the available 
anti-platelet drugs, their target as well as the associated side effects and 
limitations or the current clinical trial status. It is ironic that the most potent anti-
platelet drugs confers the greatest bleeding risk. The list is not exhaustive for all 
the current clinical trials, but it undoubtedly conveys that all anti-platelet drugs 
use independent approaches and independent approaches are in fact needed 
because each therapy has its own problems. A new mode of affecting platelet 
reactivity may prove to offer unique advantages in a host of clinical settings.  
 The platelet proteome is dynamic, with older denser platelets having 
decreased protein content. Proteasome inhibition with bortezomib is a key 
therapy for relapsing multiple myeloma, but what limits this therapy is associated 
thrombocytopenia (Lonial, Waller et al. 2005). This may be due to direct effect on 
platelets as bortezomib inhibits platelet aggregation in vitro (Avcu, Ural et al. 
2008). A second proteasome inhibitor, PSI, prevented thrombosis in 
renovascular hypertensive rats, (Ostrowska, Wojtukiewicz et al. 2004). Platelets 
contain a functional 20S proteasome and its regulatory cap (Ostrowska, 
Ostrowska et al. 2003). Platelets should also contain a functional ubiquitin-
proteasome system because collagen activation of gpVI stimulates ubiquitination 
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of platelet Syk kinase 
(Dangelmaier, Quinter et al. 2005) through the E3 ligase Cbl-b (Daniel, 
Dangelmaier et al. 2010).  
 Despite these fragmented observations, the proteasome of platelets is not 
established as a component of cell signaling or function. Based on this, the 
studies of this thesis examine the role of ubiquitin-proteasome system in 
modulating platelet function. 
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Table 1.1 Antiplatelet agents in the clinic or in clinical trials 
Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
Blockade of prostanoid 
biosyntesis (TxA2) 
Acetylsalicylic acid 
(aspirin) 
Irreversible acetylation 
of cyclooxygenase 1 
(COX-1), inhibiting 
generation of TxA2 
Bleeding, 
gastrointestinal 
toxicity Weak 
anti-platelet 
agent, ~25% 
prevalence of 
aspirin 
'resistance' 
GPIIb-IIIa inhibition Abciximab (ReoPro) Reversible inhibition of 
integrinαIIbβ3 activation, 
also blocks 
integrin αvβ3 
Bleeding, 
thrombocytopenia 
Restrictions 
because of 
intravenous 
administration 
Eptifibatide (Integrilin) Rapidly reversible, 
Arg-Gly-Asp (RGD) 
mimetic 
Bleeding, small 
increase in 
profound 
thrombocytopenia 
Restrictions 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
because of 
intravenous 
administration 
P2Y12antagonists Tirofiban (Aggrastat) RGD mimetic; rapidly 
reversible, minimal 
effects on αvβ3 
Bleeding, severe 
but reversible 
thrombocytopenia 
in small numbers 
of recipients 
Restrictions 
because of 
intravenous 
administration 
Ticlopidine (Ticlid) Active metabolite of 
parent compound 
irreversibly inhibits the 
ADP receptor P2Y12 
Bleeding, 
gastrointestinal 
toxicity, rash, 
neutropenia, 
thrombotic 
thrombocytopenic 
purpura (TTP) 
(largely replaced 
by clopidogrel 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
because of 
increased 
toxicity) 
Clopidogrel (Plavix) Active metabolite of 
parent compound 
irreversibly inhibits 
P2Y12 
Rash, 
neutropenia, 
TTP, major 
bleeding 
corresponding 
with >50% 
inhibition of 
P2Y12. 
Interpatient 
response 
variability 
Prasugrel (Effient) Active metabolite of 
parent compound 
irreversibly inhibits 
P2Y12; improved 
potency and 
consistency over 
clopidoogrel. Pro-drug 
Bleeding (more 
haemorrhagic 
side-effects than 
clopidogrel) 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
metabolism is more 
efficient. 
Ticagrelor (Brilinta) Direct and reversible 
P2Y12antagonist 
Recently approved. 
Indication is for 
use with aspirin. 
Higher rate of 
major bleeding 
(compared to 
clopidogrel); 
increased 
dyspnoea and 
ventricular 
pauses 
Agents that elevate 
camp and/or cGMP 
Dipyridamole 
(Persantine) 
Inhibitor of cyclic 
nucleotide 
phosphodiesterase 
(PDE), thromboxane 
synthase and 
adenosine deaminase. 
Also inhibits reuptake 
of adenosine; anti-
platelet activity and 
Headache, 
dizziness, 
hypotension, 
flushing, 
gastrointestinal 
toxicity, rash 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
vasodilatory properties 
Cilostazol (Pletal) Selective type 3 
phosphodiesterase 
(PDE3) inhibitor, 
elevates cAMP to 
inhibit platelet 
aggregation; causes 
arterial vasodilation 
Bleeding; 
headache; 
diarrhea; 
palpitations; 
dizziness; rash; 
pancytopaenia 
(~15% of 
individuals 
discontinue use 
because of side 
effects) 
Thrombin receptor 
antagonists 
SCH530348 
(Vorapaxar) 
High affinity, reversible 
PAR1 antagonist 
Phase 2 trials, no 
major bleeding, 
generally well 
tolerated; phase 
3 trial (TRACER) 
recently halted 
(January 2011), 
potentially 
because of 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
unacceptable 
bleeding; 
second phase 3 
trial (TRA 2P 
TIMI 50) scaled 
back for 25% of 
enrolled 
participants with 
a history of 
stroke. Further 
drug 
development is 
unclear 
E5555 (Atopaxar) PAR1 antagonist Currently 
undergoing 
phase 2 trials; 
results show a 
trend to increase 
'nuisance' 
bleeding, safety 
issues regarding 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
liver dysfunction 
and QT interval 
prolongation 
require 
addressing 
Thromboxane 
antagonism 
S-18886 (Terutroban) Selective 
prostaglandin 
endoperoxide (TP) 
receptor antagonist: 
shows anti-thrombotic, 
anti-vasoconstrictive 
and anti-
atherosclerotic 
properties 
TAIPAD study, 
well tolerated, 
with a safety 
profile similar to 
aspirin; well 
tolerated when 
taken in 
combination with 
aspirin. Currently 
under evaluation 
in a phase 3 trial 
(PERFORM) for 
secondary 
prevention of 
acute thrombotic 
complications 
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Anti-platelet strategy Drug Mechanism(s) of 
action 
Side effects and 
limitations or 
clinical trial 
status 
Isoform selective 
inhibitors of PI 3-kinase 
AZD6482 Isoform selective 
inhibitor of PI 3-kinase 
p110β 
Phase 1 trials, 
2009, acceptable 
safety and 
tolerability profile  
 
 
Table 1.1 Anti-platelet drugs, their target as well as the associated side 
effects and limitations or the current clinical trial status. The associated 
major limitation with the anti-platelet drugs in clinical practice or in clinical trial, 
bleeding, is highlighted in bold letters. Adapted from (Jackson 2011). 
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1.2 Overview of ubiquitin-proteasome system 
 Cellular proteins are subjected to a variety of post-translational 
modifications that profoundly expand the functional repertoire and dynamics of 
the eukaryotic proteome. Proteins can be modified by the covalent addition of 
small molecules such as phosphate groups (phosphorylation), methyl groups 
(methylation), sugar groups (glycosylation), acetyl groups (acetylation) or entire 
proteins (Hochstrasser 2000; Pickart 2001; Xu and Peng 2006). The first such 
protein-based modification to be described was ubiquitin (Ub). Ubiquitin is a 
small 76- amino acid regulatory protein (~ 8.5 kDa) that is evolutionary conserved 
throughout eukaryotes (only 3 amino acid difference from yeast to human), but is 
absent from members of the other two super kingdoms, the eubacteria and the 
archae bacteria (Hershko and Ciechanover 1998; Pickart and Eddins 2004).  
 The covalent decoration of cellular proteins with Ub, known as 
ubiquitination, regulates a diverse array of biological processes, including 
signaling, protein quality control, organelle biogenesis, cell cycle regulation, DNA 
repair, transcription, inflammation, stress response, endocytosis and vesicular 
trafficking (Weissman 2001; Greene, Whitworth et al. 2005; Hurley, Lee et al. 
2006; Kerscher, Felberbaum et al. 2006; Ulrich and Walden 2010). Ubiquitination 
of proteins is mediated through an enzymatic cascade that, in most cases, 
results in the conjugation of either single Ub on one (mono-ubiquitination) or 
multiple sites (multi-mono-ubiquitination), or multiple Ub monomers (poly-
ubiquitination) to the internal lysine (Lys) of a  substrate (Ravid and Hochstrasser 
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2008). However, in rare instances Ub is conjugated to the N-terminus or the side 
chain of the cysteine (Cys) moiety of the substrate (Deshaies and Joazeiro 2009; 
Komander and Rape 2012). The generation of Ub linkages with distinct 
topologies confers diversity and versatility in the ways ubiquitination modulates 
various aspects of eukaryotic biology (Weissman 2001). 
 Ubiquitination is dynamic and reversible. Removal of Ub moieties, which 
may modulate Ub signaling, is carried out by a specific class of proteases called 
deubiquitinases (DUBs). DUBs hydrolyze the isopeptide linkages between Ub 
and the substrate or between multiple Ub moieties. DUBs therefore play critical 
roles in regulating the rate of protein  turnover and in maintaining pools of free Ub 
by recycling it from existing conjugates (Amerik and Hochstrasser 2004). In 
mammalian cells, ~ 100 DUBs have been identified and classified in to five 
subfamilies (Wilkinson 1997; Reyes-Turcu, Ventii et al. 2009).  
 Among all the processes regulated by Ub, the best characterized is the 
role of poly-Ub chains in targeting the proteins for degradation by the 26S 
proteasome (Elsasser and Finley 2005; Miller and Gordon 2005). The 26S 
proteasome is a large multimeric, catalytic protease (2.5 MDa) that collaborates 
with the Ub system and ensures the precise, rapid and irreversible degradation of 
proteins tagged with poly-Ub chains. Like Ub, the proteasome is evolutionary 
conserved in eukaryotes, however, simpler forms are found even in 
archaebacteria and eubacteria. (Dahlmann, Kopp et al. 1989; Lupas, Zwickl et al. 
1994; Coux, Tanaka et al. 1996; Demartino and Gillette 2007).  The ubiquitin-
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proteasome system (UPS) is responsible for much of the regulated protein 
degradation and maintenance of protein homeostasis. Approximately 80% of 
misfolded, oxidized, or damaged proteins and short lived regulatory proteins are 
degraded by UPS (Rock, Gramm et al. 1994; Lee and Goldberg 1998). 
 Given its essential role in regulating protein turnover, defects in the 
components of UPS has been implicated in the pathogenesis of many human 
diseases, including cardiovascular diseases, neurodegenerative disorders, viral 
diseases and numerous cancers (Herrmann, Ciechanover et al. 2004; Corn 
2007; Petroski 2008; Hoeller and Dikic 2009; Lehman 2009).  
1.2.1 Ubiquitin Conjugation System 
 The covalent conjugation of Ub to substrate is achieved by the concerted 
action of three enzymes: Ub activating enzyme E1, Ub conjugating enzyme E2, 
and Ub protein ligase E3 (Fig.1.7).  Since ubiquitination controls diverse 
biological processes, not only in the cell, but also during the development of 
tissues and entire organisms (Mistry, Wilson et al. 2004; Pickart and Fushman 
2004; Kerscher, Felberbaum et al. 2006; Yanjiang, Hongjuan et al. 2012), the 
whole process is tightly regulated in a spatial and temporal manner and displays 
specificity for the substrates it modulates.  
 In the first step, Ub activating E1 enzyme activates Ub in an ATP 
dependent manner by forming a high energy thioester bond between the E1 
active site cysteine (Cys) and the carboxy terminus glycine76 (Gly76) residue of 
Ub substrate (Ciechanover, Finley et al. 1984; Hershko and Ciechanover 1998).  
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  Ub E1s (Uba1 and Uba6) are multidomain enzymes that activate and 
transfer Ub to the active site of E2s. This is critical for cellular  homeostasis  
because  chemical  inhibition  of E1  activity  in  the  cell  results  in  the  almost  
immediate shutdown  of  the  entire  UPS (Yang, Kitagaki et al. 2007). The E1 
enzyme contains two active sites, an adenylation site that binds ATP-Mg2+ and 
activates C-terminal carboxyl group of Ub, and a catalytic cysteine that attacks 
the Ub adenylate bond to form a E1~Ub thioester.  
 In the second step, "activated" thioester-bound Ub is transferred from Ub-
E1 to the active site Cys of one of a number of E2 Ub conjugating enzymes 
through a transthiolation reaction. The transfer of Ub from E1 to E2 catalytic 
cysteine residue involves conformational changes in the ubiquitin fold domain 
(UFD, E2 binding domain on E1) of E1 that facilitates the correct positioning of 
the active sites of the enzymes for efficient transfer (Huang, Hunt et al. 2007; 
Olsen and Lima 2013). The E2s are characterized by the presence of a highly 
conserved ~140 residue catalytic Ub-conjugating (UBC) fold that 
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Figure 1.7 Ubiquitin- proteasome system 
An overview of ubiquitination pathway. a) Ub is activated by an E1 in a ATP 
dependent manner and b) Ub is transferred to an E2 enzyme through a 
transthiolation reaction. Depending upon the type of  E3 ligase involved, the 
ubiquitin is sequentially transferred from E2-E3- Substrate (S) c) HECT E3s  or 
E2-Ub is directly transferred to substrate, where E3 acts as scaffold d) RING 
E3s, e) polyubiquitinated proteins are targeted to proteasome for degradation, 
while f) DUBs replete the Ub pool. adapted from (Weissman, Shabek et al. 
2011). 
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consists of 5 α-helices and 4 anti-parallel β-sheets. In the catalytic groove near 
the active site Cys is a "HPN" (histidine, proline and asparagine) motif that 
facilitates both thioester formation between "activated" Ub from E1 and the active 
site Cys of E2, and substrate ubiquitination. Both histidine and proline may play a 
role in supporting the protein structure around the active site, where as 
asparagine is critical for promoting isopeptide bond formation between Ub and a 
substrate lysine (Wu, Hanlon et al. 2003; Eletr, Huang et al. 2005; Wenzel, Stoll 
et al. 2011). The E2 Ub conjugating enzyme then catalyzes substrate 
modification in conjunction with a substrate-specific E3 Ub ligase. E2s play an 
important role in determining Ub chain length as well the linkage specificity and 
since both these factors govern the cellular fate of the target  protein, E2s are 
viewed as important regulators of Ub signaling that interact with select E3 
proteins rather than just carriers of activated Ub (Olsen and Lima 2013).  
  The E3 Ub ligases can be classified into three major types based on their 
catalytic mechanism:  the Homologous to E6-associated protein C-terminus 
(HECT)  E3s, really interesting new gene (RING) domain E3s, and structurally 
related U-box-type E3s. The HECT E3 first loads the ubiquitin from the E2 to 
their active site Cys and then shuttles it to the substrate (Bernassola, Karin et al. 
2008). On the other hand,  the RING finger domain and U-box-type E3s act as 
scaffolds that brings Ub~E2 and substrate in proximity to facilitate Ub transfer 
from Ub~E2 to substrate (Lipkowitz and Weissman 2011). However, this 
mechanistic distinction between HECT and RING E3s has become blurred with 
the identification of RING subfamily of RING-in-between-RING (RBR) E3 ligases 
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that act as RING/HECT hybrids i.e. they form a thioester~Ub intermediate via a 
conserved RING domain Cys prior to Ub transfer to substrate (Wenzel, 
Lissounov et al. 2011).  
 In mammalian cells, there are two known E1s, approximately 30-40 E2s 
and more than 600 E3s, making E3s, either alone or in association with its bound 
E2, the main specificity and selectivity factor of the UPS (Michelle, Vourc'h et al. 
2009; Schulman and Harper 2009; Voutsadakis 2010).  
1.2.2 Ubiquitin Code 
 A single round of the E1-E2-E3 enzymatic cascade results in mono-
ubiquitination of substrate i.e. a single Ub moiety binds to the substrate. 
Additional rounds have diverse outcomes: Multi-mono-Ub chains- formed when 
several single Ub moieties binds to the substrate at multiple sites and/or Poly-Ub 
chains- formed through the sequential addition of several Ub moities to the 
previously attached Ub. Poly-Ub chains can be homotypic, using the same lysine 
residue of incoming Ub moiety or heterotypic, using more than one linkage type. 
Heterotypic chains are either branched i.e. formed by ubiquitination of one Ub at 
two or more sites or non-branched. The Ub amino terminal Met1 residue (M1) 
can also participate in the Ub chain formation (Ikeda and Dikic 2008; Dikic, 
Wakatsuki et al. 2009; Komander and Rape 2012). All eight Ub-Ub linkages have 
been found to coexist in vivo (Peng, Schwartz et al. 2003; Xu, Duong et al. 
2009).  
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 Ub attachment to a target protein is more than just a terminal reaction, as 
both the length (mono-vs. poly-Ub chain) and the linkage type (homotypic or 
heterotypic) can regulate the fate, stability, activity and subcellular localization of 
the modified substrates (Pickart and Fushman 2004; Li and Ye 2008).  
 The  canonical  view  is  that  poly-ubiquitination at Lys48 (of at least  four  
Ub moieties) tags a protein for proteasome-mediated degradation (Komander 
and Rape 2012), whereas poly-ubiquitination at Lys63 is non-degradative and 
plays essential roles in DNA repair, DNA replication and signal transduction 
(Chen and Sun 2009). Unlike Lys48 and Lys63 chains, not much is known about 
"atypical chains" that are linked via Lys6, Lys11, Lys27, Lys29, Lys33 and Met1. 
Current known functions of mono and multi-mono-Ub chains as well as atypical 
chains are summarized in Fig. 1.8.  
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Histone regulation (Roest, van Klaveren 
et al. 1996; Robzyk, Recht et al. 2000), 
Endocytosis (Shih, Sloper-Mould et al. 
2000; Hicke 2001), Viral Budding, DNA 
repair and Nuclear Export (Boyd, Tsai et 
al. 2000; Geyer, Yu et al. 2000; Brooks 
and Gu 2006). 
Endosomal Trafficking (Strous and van 
Kerkhof 2002; Huang, Kirkpatrick et al. 
2006), p53 nuclear transport (Li, Brooks 
et al. 2003). 
DNA damage response. Reviewed in 
(Kulathu and Komander 2012).  
Cell cycle regulation, Membrane 
Trafficking, Endoplasmic reticulum 
associated degradation (ERAD), TNFα 
signaling.  Reviewed in (Kulathu and 
Komander 2012).   
Mitochondrial maintenance or Mitophagy 
(Geisler, Holmstrom et al. 2010; Glauser, 
Sonnay et al. 2011), Nuclear translocation 
(Peng, Zeng et al. 2011) .  
Ubiquitin-fusion degradation (Hwang, 
Shemorry et al. 2010; Metzger and 
Weissman 2010). 
T-Cell receptor signaling (Huang, Jeon et 
al. 2010).  
Nuclear factor-κB (NF-κB) signaling (Iwai 
and Tokunaga 2009), Cell cycle 
regulation (Wickliffe, Williamson et al. 
2009). 
Lys6 
Mono- 
Ubiquitination 
Multi-mono- 
Ubiquitination 
Lys11 
Lys27 
Lys29 
Lys33 
Poly- 
Ubiquitination 
Met1- 
Ubiquitination 
b 
c 
d 
a 
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Figure 1.8 The Ub code 
Ub is usually conjugated to the ε-amino group of a Lys residue in a substrate, 
however,  Ub itself possess seven lysines residues each of which, and Met1, can 
participate in chain formation and generates ubiquitin linkages of different 
topologies. This figure summarizes the type of ubiquitination and cellular fate of 
the protein. a) Mono-ubiquitination, b) Multi-mono- ubiquitination, c) Poly-
ubiquitination and d) Met1 ubiquitination. 
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1.2.3 The proteasome- a degradation nanomachine 
 The 26S proteasome is an intricate proteolytic machine that plays an 
indispensible role in the degradation of misfolded, damaged or regulatory 
proteins decorated with Ub. The proteasome is a large multimeric complex that is 
composed of a 20S catalytic core particle (CP) flanked by one or two 19S 
regulatory particles (RPs, Figure 1.9) (Coux, Tanaka et al. 1996; Baumeister, 
Walz et al. 1998; Tanaka 2009). 
1.2.3.1 20S catalytic core particle 
 The catalytic 20S core particle is the business center of proteasome. It is 
assembled into a cylindrical structure formed by axial stacking of 4 hetero-
heptamaric rings. Each ring contains 7 different homologous α-subunits and 7 
different β-subunits (Unno, Mizushima et al. 2002). The catalytic activities of the 
20S core particle are associated with β-subunits with β1-subunit having caspase-
like (cleaves after acidic residues), β2-subunit having tryptic-like (cleaves after 
basic residues) and β5-having chymotrypsin-like activity (cleaves after 
hydrophobic residues) (Orlowski 1990; Kisselev, Akopian et al. 1999). The 
combination of three different peptidase activities confers to the 20S core particle 
the ability to degrade a broad variety of peptide sequences with high efficiency 
and specificity. The inactive β-subunits are required for proper assembly and 
maturation of catalytically active β-subunits (Arendt and Hochstrasser 1999). 
Following degradation, the length of majority of the newly created peptides range 
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from 3-15 amino acids that are then hydrolyzed to amino acids by 
oligopeptidases and/or amino carboxyl peptidases (Glickman and Ciechanover 
2002; Tanaka 2009) or the short peptides are presented to class I MHC 
molecules for antigen presentation to the immune system (Saeki and Tanaka 
2012). 
 Outer α-rings serve as a gated channel to regulate the substrate entry into 
the catalytic core. The substrate bound for degradation must pass through this 
channel, lined by α2-, α3- and α4-subunits, to enter the catalytic chamber 
(Zwickl, Grziwa et al. 1992; Lowe, Stock et al. 1995). The outer α-rings provide 
binding sites for the 19S regulatory particle and their interaction results in a 
conformational change in the α-subunits that allow entry of the protein substrate 
into the central chamber of the 20S core particle (Smith, Chang et al. 2007). 
1.2.3.2 19S regulatory particle (19S RP) 
 The  19S regulatory particle is a ~900 kDa complex that plays  an  
essential  role  in  the recognition, deubiquitination, unfolding of ubiquitinated 
substrate and in translocation of the unfolded substrate into the 20S core particle 
for degradation (Coux, Tanaka et al. 1996; Baumeister, Walz et al. 1998; Tanaka 
2009). The 19S regulatory particle contains at least 19 subunits that can be 
subdivided into two groups: regulatory particle of non-ATPase (Rpn) and 
regulatory particle of triple-ATPase (Rpt). Biochemical experiments have 
organized the 19S RP into two sub-complexes: the lid and the base (Lander, 
Estrin et al. 2012).  
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Figure 1.9 The 26S proteasome 
a)   The 26S proteasome is comprised of 20S core particle flanked by two 19S 
regulatory particles. b) Individual subunit composition of 26S proteasome.  The 
19S regulatory particle is organized into two sub-complexes, lid and base, and 
the catalytic 20S core is arranged as a cylindrical barrel made up of 2 outer α- 
and 2 inner β-rings.  Adapted from (Murata, Yashiroda et al. 2009). 
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 The lid is composed of 9 non-ATPase subunits (Rpn3, Rpn5–Rpn9, 
Rpn11, Rpn12, and Rpn15). The lid subunits, Rpn3, Rpn5, Rpn6, Rpn7, Rpn9 
and Rpn12 contain protein–protein interaction motifs called PCI [proteasome–
CSN (COP9 signalosome)–eIF3 (eukaryotic translation initiation factor 3)] and 
function as scaffolding subunits (Finley 2009). The best established function of 
the lid is deubiquitination. Rpn11, which is a JAB1–MPN–MOV34 (JAMM) 
domain containing DUB, tightly couples deubiquitination and substrate 
degradation (Bar-Nun and Glickman 2012). Rpn8 acts as a  non-catalytic binding 
partner of Rpn11 (Finley 2009).   
 The base contains six ATPases (Rpt1-Rpt6),  two large scaffolding 
subunits (Rpn1 and Rpn2) and two Ub receptors (Rpn10 and Rpn13) that 
efficiently trap Ub-conjugated substrates (Finley 2009). The 6 triple-ATPases 
form a hetero-hexameric ring with the specific order of Rpt1-Rpt2-Rpt6-Rpt3-
Rpt4-Rpt5 to constitute the molecular motor of proteasome (Tomko, Funakoshi et 
al. 2010). The ATPase subunits provide the energy needed for deubiquitination, 
substrate unfolding, and translocation of the substrate through the narrow pore 
into the degradation chamber (Martin, Baker et al. 2008; Maillard, Chistol et al. 
2011). The binding of C-terminus tails of ATPases Rpt2, Rpt3 and Rpt5 on 
dedicated sites on the 20S core particle (inter-subunit pockets formed by α-
subunits of the outer ring)  triggers gate opening and facilitating substrate entry 
(Smith, Chang et al. 2007; Gillette, Kumar et al. 2008).  
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 The major activity of the lid and the base is proposed to be 
deubiquitination. In mammalian cells, two DUBs, USP14 and UCHL5, are 
associated with the base complex and they progressively trim poly-Ub chains 
from the distal end of the chains. USP14 is associated with Rpn1 (Hu, Li et al. 
2005) and UCHL5 binds to Rpn2 via Rpn13 (Hamazaki, Iemura et al. 2006; Yao, 
Song et al. 2006).  
1.2.4 Deubiquitination 
 DUBs  are isopeptidases that play pivotal roles in Ub-mediated signaling 
pathways. They are classified into six subclasses: Ub C-terminal hydrolases 
(UCHs), Ub specific proteases (USP’s), ovarian tumor proteases (OTUs), 
Josephines, JAB1/MPN/Mov34 metalloenzyme (JAMM) and monocyte 
chemotactic protein-induced protein (MCPIP). Except for JAMM proteases, which 
are Zn2+ metalloproteases, the rest are cysteine proteases (Fraile, Quesada et al. 
2012; Lim and Baek 2013).  
 DUBs hydrolyze isopeptide bonds in Ub-protein conjugates and are vital 
for Ub homeostasis. General cellular roles of DUBs are summarized in Fig. 1.10. 
DUBs regulate ubiquitination in a spatio-temporal manner. DUBs can pair with 
E3s ligases, which have inherent autoubiquitination activity, in order to prevent 
their self-ubiquitination and degradation, e.g. USP8 mediated stabilization of 
neuregulin receptor degradation protein 1 (Nrdp1) ligase induces degradation of 
its substrate ErbB3 (Cao, Wu et al. 2007). The DUB-E3 pairing can also fine tune 
editing of one Ub signal for another e.g. cellular inhibitor  of  apoptosis  (cIAP)  
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ubiquitin ligases ubiquitinate receptor-interacting serine-threonine kinase 1 
(RIPK1) at Lys63, but in order to turn off the signaling, A20 depolymerize Lys63 
chains and facilitate the polymerization of Lys48-linked chains on RIPK1 resulting 
in its degradation (Hymowitz and Wertz 2010).  
 DUBs  display specificity at multiple levels as evident by their ability to 
distinguish between different Ub chain linkages and chain structure (Komander, 
Clague et al. 2009). Different subclasses have preference for specific chain 
linkages e.g.  USP14, OTUB1 and A20 process Lys48-linked chains, where as 
JAMMs and CYLD  prefer Lys63- linked chains (Fraile, Quesada et al. 2012). 
DUBs also modulate protein stability by removing the degradative signal from 
proteins meant for degradation or even reverse Ub signaling by removing even 
non-degradative signal.  
 As mentioned before, three DUBs directly associate with 19S regulatory 
particles and their activity can prevent degradation of protein even at the face of 
the proteasome (Guterman and Glickman 2004). The three DUBs associated 
with 19S regulatory particle are Rpn11, USP14 and UCHL5. Rpn11, a JAMM 
metalloprotease, is a constituent subunit of 19S RP and is  responsible for bulk of 
proteasome DUB activity.  Rpn11 prefers Lys63- linked chains and cleaves at the 
base of the Ub chain resulting in the release of entire poly-Ub chain (Shen, 
Schmitt et al. 2013). USP14 is associated with Rpn1 subunit of 19S RP and this 
association increases its activity by several hundred fold (Hu, Li et al. 2005). 
USP14 prefers Lys48- linked chains and to cleave at the distal end or within the 
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polymeric chain. USP14 is crucial for Ub recycling as inhibition of USP14 leads to 
increased Ub degradation resulting in the reduction of monomeric Ub. Unlike 
Rpn11, USP14 is not a constituent subunit of proteasome and may be involved in 
other cellular processes (Hanna, Hathaway et al. 2006; Koulich, Li et al. 2008; 
Shen, Schmitt et al. 2013). UCHL5 binds to 19S RP subunits, Rpn2 via Rpn13, 
and this association is required for its full activation (Hamazaki, Iemura et al. 
2006; Yao, Song et al. 2006). An excellent example of temporal regulation of Ub 
signaling is UCHL5 that catalyzes nucleosome sliding by pairing with the inositol-
requiring 80 (INO80) chromatin-remodeling complex (Grabbe, Husnjak et al. 
2011).  
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Figure 1.10 General functions of DUBs 
DUBs a) cleave Ub from its precursor molecules and generates active single Ub 
molecules b) Rescue proteins destined for degradation or c) remove non- 
degradative regulatory signal from the protein d) are crucial for Ub homeostasis 
as they remove Ub from a substrate before its degradation e) maintain free Ub 
pool by removing Ub from unanchored poly-Ub chains f) might edit Ub chains by 
swapping one signal for another and hence change the cellular fate of the target 
substrate. Adapted from (Komander, Clague et al. 2009). 
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1.2.5 Targeting UPS 
 Regulated proteolysis by UPS controls almost all aspects of cellular 
physiology and it is no wonder that defects in the components of UPS have been 
implicated in the pathogenesis of several human diseases (Herrmann, 
Ciechanover et al. 2004; Corn 2007; Petroski 2008; Hoeller and Dikic 2009; 
Lehman 2009; Schlossarek, Frey et al. 2014). The incentives of targeting this 
intricately regulated system seems obvious, and the expedited approval of 
bortezomib (PS-341, Velcade ®; Millennium Pharmaceuticals), to become first 
FDA approved proteasome inhibitor in clinical practice,  for the treatment of 
multiple myeloma  and  mantle cell lymphoma has corroborated UPS and its 
components as legitimate therapeutic targets. (Kane, Bross et al. 2003; Fisher, 
Bernstein et al. 2006). 
  Fast track approval of an improved proteasome inhibitor that overcomes 
bortezomib resistance and has a superior toxicity profile, [Carfilzomib (Kyprolis, 
Onyx Pharmaceuticals)], for multiple myeloma by the FDA and several orally 
bioavailable proteasome inhibitors in clinical trials clearly demonstrate the 
effectiveness of targeting this pathway (Kuhn, Chen et al. 2007; Herndon, 
Deisseroth et al. 2013; Shen, Schmitt et al. 2013).  Given the success of 
proteasome inhibitors in the treatment of cancer and advances in our 
understanding of UPS and its components, several small molecule inhibitors 
have been developed or are in the pipeline that target  specific components of 
this pathway e.g. MLN4924 (NAE, Millenium). This is a small molecule inhibitor 
for E1 enzyme of a Ub like protein NEDD8, and is in a phase 2 clinical trial 
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(Soucy, Smith et al. 2009). Several small molecules targeting E3 ligases are 
either in Phase I clinical trials or are in the preclinical phase  (Shen, Schmitt et al. 
2013). DUB inhibitors are recent and a USP7/HAUSP inhibitor is already in active 
preclinical development owing to its role in p53 regulation (Shen, Schmitt et al. 
2013). A novel small molecule inhibitor b-AP15 that reversibly targets 
proteasomal DUBs, USP14, and UCHL5, has anti-cancer properties and it even 
induced cytotoxicity in bortezomib-resistant cells (D'Arcy, Brnjic et al. 2011).  
 Taken together, targeting UPS for human therapy seems promising, and 
small molecule inhibitors targeting specific and smaller portions of UPS pathway 
have shown encouraging results. Platelets also have components of UPS 
(Burkhart, Vaudel et al. 2012) system, but the exact role of UPS in modulating 
platelet function is not clear. However, older platelets have a reduced proteome 
compared to newly released platelets suggesting a role of proteasome in 
platelets (Ault, Rinder et al. 1992). 
 The studies in this thesis were conducted using small molecule inhibitors 
targeting different components of the Ub-proteasome pathway in order to gain 
mechanistic understanding of the potential role of this indispensible system in 
modulating platelet reactivity.  
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CHAPTER II 
Proteasome proteolysis supports stimulated platelet function 
and thrombosis 
2.1 Introduction 
 Proteasome inhibitors are widely used for the treatment of hematologic 
cancers, specifically relapsed/refractory multiple myeloma and mantle cell 
lymphoma, (Kane, Bross et al. 2003; Adams 2004; Kane, Dagher et al. 2007) yet 
little is known of their impact on platelet function and hemostasis. Potentially, 
these agents may also target platelets because a cyclic course of the 
proteasome inhibitor bortezomib (Velcade®) induces significant cyclic 
thrombocytopenia, (Lonial, Waller et al. 2005) and proteasome inhibition hastens 
platelet death and turnover (Nayak, Kulkarni et al. 2013). Bortezomib therapy 
also associates with reduced thrombosis (Zangari, Guerrero et al. 2008; Shen, 
Zhou et al. 2011). Beyond this, there is little evidence of proteasome action on 
the platelet proteome, their activation, or on thrombosis. 
 Platelets are recruited to the vascular wall at high shear through the GPIb-
IX-V receptor complex, (Goto, Ikeda et al. 1998) where the GPIbα subunit binds 
von Willebrand factor (VWF) (Kroll, Harris et al. 1991) while its C-terminal 
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cytoplasmic domain interacts with the actin binding protein Filamin A with high 
affinity (Ithychanda, Hsu et al. 2009). This interaction tethers the receptor 
complex to the platelet cytoskeleton, maintaining the cytoskeletal architecture of 
resting platelets and those adhering in vessels at high shear rates (Cranmer, 
Ashworth et al. 2011). The GPIbα subunit also contains a high affinity binding site 
for thrombin that contributes to platelet activation when thrombin concentrations 
are low (Greco, Tandon et al. 1996). These interactions are essential for 
thrombosis (Guerrero, Shafirstein et al. 2008). Thrombotic platelet deposition is 
modeled in mice by FeCl3 induced injury of carotid arteries (Li, Febbraio et al. 
2010; Li, McIntyre et al. 2013) resulting in rapid platelet adhesion and formation 
of an occlusive platelet-rich thrombus at the site of injury.  
 Nucleated cells remove proteins from their proteome by proteasome-
catalyzed proteolysis. This multimeric complex consists of a 20S catalytic core of 
non-catalytic α-subunits and three distinct β-subunits that hydrolyze peptide 
bonds of unfolded protein substrates by β1 caspase-like hydrolysis, β2 tryptic 
hydrolysis, and β5 chymotryptic cleavage (Chen and Hochstrasser 1996; Arendt 
and Hochstrasser 1997; Dick, Nussbaum et al. 1998; Nussbaum, Dick et al. 
1998). The proteasome is capped by a 19S regulatory subunit that conducts 
substrate recognition, deubiquitination, unfolding, and protein translocation into 
the 20S core (Dahlmann, Ruppert et al. 2000; Dahlmann, Ruppert et al. 2001) 
Substrates for proteasome hydrolysis are recognized by the 19S core through 
the covalent conjugation of monomeric or polymeric chains of the ~8 kDa 
ubiquitin to the targeted protein (Nalepa, Rolfe et al. 2006; Jacobson, Zhang et 
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al. 2009; Xu, Duong et al. 2009). 
 Platelets contain several components of the 20S proteasome core 
(Yukawa, Sakon et al. 1993; Ostrowska, Wojcik et al. 1997; Ostrowska, 
Ostrowska et al. 2003; Avcu, Ural et al. 2008) and possess at least the 
chymotryptic activity of the proteasome (Nayak, Kumar et al. 2011). In addition, 
platelets have components of UPS (Burkhart, Vaudel et al. 2012) system, but the 
exact role of UPS in modulating platelet function is not clear.  Platelets should 
contain functional E1 ubiquitin activating activity and E2/E3 ligases because 
collagen activation of gpVI stimulates ubiquitination of platelet Syk kinase 
(Dangelmaier, Quinter et al. 2005) through the E3 ligase Cbl-b (Daniel, 
Dangelmaier et al. 2010). Furthermore, clinical inhibitor of proteasome 
(bortezomib) reduced ADP-induced aggregation (Avcu, Ural et al. 2008) and 
platelets isolated from patients receiving bortezomib therapy are hyporesponsive 
to other stimuli (Zangari, Guerrero et al. 2008; Shen, Zhou et al. 2011).  
Moreover, older platelets have a reduced proteome compared to newly released 
platelets suggesting a role of proteasome in platelets (Ault, Rinder et al. 1992). 
     Here we show the expression of a functional ubiquitin/ proteasome 
system in platelets. By investigating the impact of proteasome inhibition on a well 
established mouse model of thrombosis and on a range of ex vivo activities, we 
conclusively demonstrate that the platelet proteasome contributes to cellular 
activation and function. Therapeutic proteasome inhibition in platelets produces a 
hypothrombotic state, and might also augment anti-platelet therapy. 
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2.2 Materials and Methods 
2.2.1 Chemicals and reagents 
 Chemicals and reagents were purchased from: sterile ﬁltered hanks 
balanced salt solution (HBSS) and sterile tissue culture plates (Falcon Labware); 
endotoxin-free human serum albumin (25% human albumin solution, Baxter 
Healthcare); endotoxin-free PBS, phenol-extracted LPS (Escherichia coli 
O111:B4) free of lipoprotein contamination (List Biological Laboratories); 
recombinant soluble CD14, recombinant lipopolysaccharide-binding protein 
(LBP), Allophycocyanin (APC)-anti-human vWF (R&D Systems); anti-
polyubiquitin antibodies FK1 and FK2, anti-UBE1, UbiQapture™-Q kit (Enzo 
lifesciences); anti-Filamin A, anti-Talin1 (C45f1), anti-β-actin and anti-skp1 (Cell 
signaling); anti-Cul5 and anti-Asb2 (Abcam); anti-talin 1(YQ 16), anti-GPVI, anti-
p53 and SZ2 antibody (SCBT); p53 ubiquitination kit, anti-UBcH 1,5 and 7, anti-
RPN2 and anti-11S-α subunit (Boston Biochem); MG132, AYPGKF (PAR4 
agonist peptide), SFLLRN (PAR1 agonist peptide) and RWJ56110 (Tocris); 
Bortezomib (Eurasia); Antichrome TF® (American Diagnostica); Phycoerytherin 
(PE)-anti-human CD42b (Millipore); fluorescein isothiocyanate (FITC)- CD36 
(Cayman Chemicals); Calcein AM and Fura-2 AM (InvitrogenTM); Ristocetin and 
Botrocetin (Sigma-Aldrich). Other chemicals were from Sigma-Aldrich or Biomol 
Research Laboratories.  
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2.2.2 Platelet preparation 
 Human blood was drawn into acid-citrate-dextrose and centrifuged (200 × 
g, 20 min) without braking to obtain platelet-rich plasma in a protocol approved 
by the Cleveland Clinic Institutional Review Board. Purified platelets were 
prepared as stated (Brown and McIntyre 2011). Briefly, platelet-rich plasma was 
filtered through two layers of 5-μm mesh (BioDesign) to remove nucleated cells 
and recentrifuged (500 × g, 20 min) in the presence of 100 nM PGE1. The pellet 
was resuspended in 50 ml PIPES/saline/glucose (5 mM PIPES, 145 mM NaCl, 4 
mM KCl, 50 μM Na2HPO4, 1 mM MgCl2, and 5.5 mM glucose) containing 100 nM 
PGE1. These cells were centrifuged (500 × g, 20 min) and recovered platelets 
were centrifuged again before resuspension in 0.5% human serum albumin in 
HBSS. For pure platelets, cells were resuspended in AutoMACS sample buffer, 5 
μl anti-CD45, anti-CD15, anti-CD14, and anti-glycophorin–coated magnetic 
beads (Miltenyi Biotec) per 109 cells for 25 min with constant rotation before 
purification in an AutoMACS magnetic separator (Miltenyi Biotec). 
2.2.3 Proteasome function 
 Proteasome-Glo™ 3-Substrate System (Promega) separately assayed 
hydrolysis of luminogenic substrates for the three proteasome activities 
[chymotryptic (Suc-LLVY-aminoluciferin), tryptic (Z-LRR-aminoluciferin), and 
caspase-like or postglutamyl peptide hydrolase (Z-nLPnLD-aminoluciferin)]. 
Washed platelets (4 X 108/ml) were pretreated with or without 30 µM MG132  for 
30 min, pelleted and lysed using NP-40 lysis buffer (150 mM NaCl, 25 mM Tris 
[pH 7.6], 1% nonidet P-40, 2 mM EDTA, 1 mM sodium orthovanadate, 10 mM 
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sodium fluoride, 100 µM PMSF, 1 µg/mL pepstatin, and 10 µg/mL leupeptin to 
inhibit non-proteasome proteases) and incubated with luminogenic substrates for 
30 min before luminescence was measured. Addition of protease inhibitors make 
sure that cellular proteases don't cleave the substrate and only  
2.2.4 In vivo thrombosis 
 Twelve week old C57BL6 mice were anesthetized with ketamine (90 
mg/kg)/xylazine (15 mg/kg) and the right jugular vein and the left carotid artery 
were exposed via a middle cervical incision. Platelets were labeled by injecting 
100 μl of rhodamine 6G (0.5 mg/ml) in saline into the right jugular vein. MG132 
(30 µM in DMSO; 6 mg/kg) or DMSO vehicle (10.5 µl) was added to the above 
solution, and the drug was allowed to circulate for 15 min before FeCl3 injury (Li, 
Febbraio et al. 2010; Li, McIntyre et al. 2013). Thrombosis was induced in the left 
carotid artery by stripping the adventitia and placing a piece of black plastic 
under the vessel to reduce background fluorescence. A 1 X 2 mm piece of filter 
paper saturated with 7.5% FeCl3 was applied to the carotid artery for 1 minute, 
the filter paper was removed, and the vessel rinsed with saline. Fluorescent 
thrombus formation was observed in real-time under a water immersion objective 
at 10 X magnification. Time to occlusive thrombosis was determined offline using 
video image capture with a QImaging Retigo Exi 12-bit mono digital camera 
(Surrey, Canada) and Streampix version 3.17.2 software (Norpix, Montreal, 
Canada). The end points were set as either cessation of blood flow for >30 
seconds or no occlusion after 30 minutes (three times longer than the average 
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occlusion time), in which case the time was recorded as 30 minutes for statistical 
comparison. 
2.2.5 Platelet transfusion and murine carotid artery thrombosis assay 
 Eight week old female platelets donor mice were anesthetized with 
ketamine (100 mg/kg) and xylazine (10 mg/kg) and 700 μl blood was obtained 
from inferior vena cava puncture into 1 ml syringe containing 100 μl sodium 
citrate (0.109 M).  Blood was transferred into a 2 ml tube containing 800 μl 
Tyrode’s buffer and platelet-rich plasma (PRP) were gathered by centrifugation at 
100g for 10 minutes.  PRP was further centrifuged at 100g for 10 minutes in the 
presence of PGE1 to pellet platelets. 10
9 platelets resuspended in 500 μl saline 
were treated with MG132 (30 uM) or vehicle for 30 min, centrifuged and re-
suspended in 200 μl saline. 
Recipient wild type mice were exposed to 11Gy of external beam 
irradiation from a Cesium 137 source to induce thrombocytopenia with platelet 
counts <5% of normal after 5~6 days (Chen, Febbraio et al. 2008). At sixth days 
after irradiation, the thrombocytopenic WT mice (8 weeks old) were anesthetized 
as before and the right jugular veins and the left carotid artery exposed via a 
middle cervical incision (Li 2013). The pre-treated donor platelets were then 
fluorescently stained by adding 100 μl of rhodamine 6G solution (0.5 mg/ml in 
saline), and injected through the jugular vein of thrombocytopenic mice 10 
minutes prior to carotid injury to allow the transfused platelets to reach 
equilibrium in the circulation.  Vehicle DMSO treated platelets were used as 
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controls.  Details of this thrombosis model have been described previously (Li 
2013).   
2.2.6 p53 ubiquitination 
 Washed platelets (109/ml) were lysed in NP-40 lysis buffer and incubated 
with components from a p53 ubiquitination kit (Boston Biochem), but lacking 
recombinant E1, for 60 min before the reaction was stopped with 2X reducing 
SDS sample buffer. The products were resolved by SDS-PAGE, and p53 
ubiquitination status determined by western blotting with anti- p53 antibody. 
2.2.7 Western blotting and liquid chromatography-mass spectrometry 
 Washed platelets (4 X 108/ml) were treated with 30 µM MG132 or buffer 
for 30 min before treatment with thrombin (0.2 U) or ADP (100 µM). After 
incubation, platelets were pelleted and lysed using radioimmunoprecipitation 
assay (RIPA) lysis buffer [150 mM NaCl, 25 mM Tris (pH 7.6), 1% Nonidet P-40, 
0.1% sodium dodecyl sulfate, 0.5% deoxycholate, 2 mM EDTA, 1 mM EGTA, 1 
mM sodium orthovanadate, 10 mM sodium fluoride, 100 µM phenylmethylsulfonyl 
fluoride, 1 µg/mL pepstatin, and 10 µg/mL leupeptin]. Samples were kept on ice 
for 30 min with occasional vortexing to ensure complete lysis before 
centrifugation (21,000 x g, 10 min). Reducing SDS sample buffer was added 
before the proteins were resolved by SDS-PAGE.  
     Three different LC-MS/MS experiments were performed, an identification 
experiment, truncation analysis with N-terminal tagging, and truncation analysis 
with chymotryptic digestion with multiple reaction monitoring (MRM).  For all of 
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these experiments the SDS-PAGE bands were excised from the Coomassie 
stained gels, washed, reduced and alkylated prior to in-gel digestion with either 
trypsin (identification and TMT N-terminal tagging experiments) or chymotrypsin. 
The N-terminal tagging was performed on extracted peptides by adding 100 µl of 
the tandem mass tags (TMT, Thermo scientific) in 200 mM triethyl ammonium 
bicarbonate for 1 hr. The reaction was quenched by 5% hydroxylamine for 15 
min, combined, dried by speedvac, and dissolved in 1% acetic acid.  
     Two different LC-MS/MS systems were used in these experiments.  Protein 
identification and MRM analysis was carried out on a LTQ linear ion trap 
equipped with an Eksigent nano-1D HPLC system.  Peptides were resolved on a 
self-packed Phenomenex Jupiter C18 column (8 cm x 75 µm) with an 
acetonitrile/0.1% formic acid gradient.  The instrument was operated in a either a 
data dependent mode in which a mass scan was followed by MS/MS scans on 
the most abundant ions or Multiple Reaction Monitoring (MRM) mode in which 
specific ions are fragmented and assessed over the entire course of the LC 
experiment.  Proteins were identified by searching the LC-MS/MS spectra 
against the human reference sequence database with the program Mascot.  The 
TMT-Tagged samples were analyzed on an LTQ-Orbitrap-Velos hybrid mass 
spectrometer equipped with an Eksigent nano-1D HPLC system.  Peptides were 
resolved on a PicoFrit column packed with ProteoPep 2 (10 cm x 75 µm) C18 
with an acetonitrile/0.1% formic acid gradient. The instrument was operated in a 
data dependent mode in which all high resolution mass scans were obtained in 
the Orbitrap (resolution at 60,000) to identify the five most abundant ions.  These 
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ions were then subjected to five MS/MS scans in the LTQ for peptide 
identification, and five HCD (higher energy collisional dissociation) scans in the 
Orbitrap for TMT Tag quantitation.    The resulting data was then searched 
against the human reference sequence database 
(http://www.ncbi.nlm.nih.gov/RefSeq/) using the program SEQUEST.  The search 
parameters include 10 ppm parent ion tolerance, 0.8 Da MS/MS tolerance, full 
tryptic peptides, oxidized methionine as a variable modification, 
carbamidomethylated cysteines and TMT tag modifications as static 
modifications.  Positive protein identifications were determined by setting the 
FDR rate to less than 1% and requiring at least 2 peptides per protein.  Peptide 
TMT quantitation was performed by Proteomics Dynamics Software with an 
integration window tolerance of 20 ppm and monoisotopic masses for the tabs at 
126.127 and 127.131 Da. 
2.2.8 Total internal reflection microscopy (TIRF) microscopy 
 Washed platelets (2 X 108/ml) were treated with 30 µM MG132 or not for 
30 min before addition onto a drop of 0.025 U thrombin placed in a glass 
bottomed microwell (MatTek) dish. Imaging was performed using at 100X with a 
1.46 N.A. objective in a Leica AM TIRF MC System (Leica Microsystems, 
Wetzlar, Germany) equipped with an ImageEM C9100-13 EMCCD camera 
(Hamamatsu, Bridgewater, N.J). The 488 nm 10-mW diode laser was used for 
excitation and the penetration depth was set to 70 nm. Within 10 seconds of 
being placed on the stage, the sample was focused and a time-lapse series was 
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initiated to collect images every 3 seconds for 5 minutes. At the end of the series, 
five static images were collected in both TIRF and differential interference 
contrast (DIC) modes of five different fields in the sample.  
2.2.9 Microparticle isolation and quantitation 
 Washed platelets (109/ml) were pretreated with 30 µM MG132, 40 µM 
bortezomib or buffer for 30 min before an overnight treatment with thrombin (0.2 
U), ADP (100 µM) or 0.1 g/ml LPS with addition of 0.1 g/ml each of human 
recombinant CD14 and LPS binding protein (LBP). Platelets were removed twice 
by centrifugation (500 x g) before microparticles were collected by centrifugation 
(100,000 x g, 90 min). The microparticle pellet was resuspended in 0.5 % human 
serum albumin/HBSS MPs and were counted by flowcytometery using defined 
numbers of 3-m polystyrene latex beads (Sigma) as an internal standard for 
size. Forward scatter (FSC) and side scatter (SSC) were drawn to include 50,000 
3-m events. Microparticle size was determined using 1-m beads (Sigma). 
Flowcytometery was performed using settings where the threshold was lowered 
to 200 and FSC and SSC gates were drawn to include events 1-m in size or 
smaller. Microparticles express phosphatidylserine on their surface which can be 
detected by annexin-V staining. Based on the flowcytometer size gating, only 
microparticles (1-m ) stained with annexin-V were enumerated.  
2.2.10 Peptidyl activity of tissue factor (TF) on microparticles 
 Tissue factor (TF)-dependent procoagulant activity was assessed with an 
Actichrome TF assay (American Diagnostica) kit as previously described (Del 
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Conde, Shrimpton et al. 2005). Washed platelets (109/ml) were pretreated with 
30 µM MG132 for 30 min before an overnight treatment with thrombin (0.2 U). 
Platelets were removed twice by centrifugation (500 x g) before microparticles 
were collected by centrifugation (100,000 x g, 90 min). The microparticle pellet 
was resuspended in 0.5% human serum albumin/HBSS and were immediately 
placed in 25 μl of kit assay buffer and TF was calculated. The data are displayed 
as fold increase in peptidyl activity of TF on microparticles at absorbance 405 
nm. 
2.2.11 Clot retraction 
 Washed platelets (5 X 108/ml) were incubated with MG132 (30 µM, 30 
min) before fibrinogen was added to a ﬁnal concentration of 500 µg/mL and 
dispensed (500 µl) into siliconized glass tubes. Clot retraction was initiated by the 
addition of human α-thrombin (0.2 U/mL) with clot volume imaged over time. The 
size of the retracted clot was determined at stated times using Imagepro plus 
software (Media Cybernatics, Bethesda,MD) to calculate retraction. 
2.2.12 Aggregation 
 Washed platelets (2 X 108/ml) were pretreated with combinations of 30 µM 
MG132, 40 µM bortezomib, 10ng SZ2, 35 nM RWJ56110 (PAR1 receptor 
inhibitor) or buffer for 30 min before stimulation with low (0.025 U) or high 
concentrations of thrombin (0.1 U) or 50 µM SFLLRN (PAR1 specific agonist). 
Platelet aggregation was measured by transmittance (Chronolog) with stirring 
(600 rpm). For ristocetin or botrocetin induced agglutination, washed platelets (2 
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X 108/ml) were resuspended in a buffer containing 50% HBSS-A and 50% 
platelet poor plasma (PPP) and were pretreated with 30 µM MG132, 40 µM 
bortezomib or buffer for 30 min. Agglutination was induced with either 650 µg/ml 
ristocetin or 300 ng/ml botrocetin and was measured by transmittance 
(Chronolog) with stirring (1000 rpm). 
2.2.13 Flow cytometry  
 Washed platelets (2 X 108/ml) were pretreated with 30 µM MG132 or 
buffer for 30 min before stimulation with 0.025 U thrombin (30 min) followed by 
fixation with 2% paraformaldehyde. Anti-CD42b antibody or non-immune isotype 
control (Millipore) was used to determine the surface expression of GPIbα by flow 
cytometery.  
2.2.14 Expression of data and statistics 
 All experiments were performed at least three times with cells from 
different donors, and all assays were performed in triplicate. The standard errors 
of the mean from all experiments are presented as error bars. Figures and 
statistical analyses were generated with Prism4 (GraphPad Software). A value of 
p≤ 0.05 was considered statistically significant. 
2.3 Results 
2.3.1 The platelet proteasome aids occlusive thrombosis  
 Human platelets expressed all three primary proteolytic activities of the 
proteasome, effectively hydrolyzing peptides through chymotryptic, tryptic and 
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caspase-like cleavage (Fig. 2.1 A). The luminescent product was the same for 
each luminogenic proteasome substrate, so the caspase-like activity was 
approximately four times more efficient than either the tryptic or chymotryptic 
activity. The trimeric leucinyl proteasome inhibitor MG132 at 30 M completely 
blocked platelet chymotryptic and caspase-like activities, and reduced the tryptic 
activity by half. MG132 at 30 µM is just optimally inhibitory (Fig. 2.1 B). Murine 
platelets also hydrolyzed these three substrates at equivalent ratios (Fig. 2.1 C) 
indicating that murine platelets have active proteasome. 
 We determined whether proteasome inhibition affected thrombosis by 
systemically injecting MG132 into BL6 mice to achieve an estimated initial 
circulating concentration of 30 µM along with rhodamine dye to fluorescently 
label circulating platelets. We initiated occlusive thrombosis 15 min later (after 
MG132 or DMSO injection) in a surgically exposed external carotid artery by a 
brief ectopic application of 7.5% FeCl3 (Li, Febbraio et al. 2010; Li, McIntyre et al. 
2013). This oxidative insult to the vascular wall resulted in the deposition of 
fluorescently labeled platelets along the damaged vessel wall that increased over 
several minutes (Fig. 2.1 D). Typically, complete occlusion of the vessel occurred 
by 10 min after FeCl3 treatment, but in animals previously injected with MG132 
occlusion was significantly delayed to 25 min (Fig. 2.1 E). 
 The delay in thrombosis after systemically administering MG132 need not 
solely reflect participation of platelet proteasomes in thrombosis. We therefore 
isolated and washed platelets from wild-type BL6 mice and treated these isolated 
cells with 30 µM MG132 or buffer, washed the cells by centrifugation and 
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transfused these cells into mice previously rendered thrombocytopenic by 
gamma irradiation.  We induced carotid artery thrombosis with ectopic FeCl3 as 
before to find control platelets were fully functional and occluded the carotid 
artery by 10 min (Fig. 2.1 F). We again found occlusive thrombosis was delayed 
in mice reconstituted with platelets treated with MG132 ex vivo. The platelet 
proteasome thus participates in arterial thrombosis. 
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Figure 2.1 Platelets express a functional proteasome that contributes to 
occlusive thrombosis 
 (A) Platelets contain a functional proteasome. Proteasome proteolytic activities 
were individually assayed using luminogenic substrates for indicated catalytic 
activities in lysates of untreated and MG132-treated platelets (n=3; **p≤ 0.01). (B) 
Proteasome proteolytic activities were individually assayed as mentioned in 
panel (A) in lysates from untreated platelets and platelets treated with different 
concentrations of MG132 (10, 20, 30 and 40 µM), n=6; ***p<0.001, **p≤ 0.01). (C) 
Mouse platelets contain a functional proteasome. Proteasome proteolytic 
activities were individually assayed in mouse platelet lysates using luminogenic 
substrates for indicated catalytic activities (n=4). (D) Fluorescent platelet 
accretion after FeCl3 damage to carotid arteries is reduced by MG132. Video 
frames at 1 min intervals of thrombus formation in FeCl3-damaged carotid 
arteries (n=5). (E) MG132 lengthens the time to vascular occlusion. Time to 
cessation of blood flow in mice treated as in the preceding panel determined by 
cessation of platelet movement (n=8 experimental, 6 control; ***p≤ 0.001).   (F) Ex 
vivo MG132 pretreatment of platelets prolongs occlusion time after transfusion 
into irradiated thrombocytopenic mice. Platelets from donor mice were first 
pretreated for 30 min with MG132 and were washed before transfusion into 
normal BL6 mice and FeCl3-induced thrombosis of carotid arteries initiated 15 
min later (n=4 experimental, 3 control; *p≤ 0.05).   
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2.3.2 Platelets contain a stimulatable ubquitination system 
  Modification of platelet function by MG132 suggests platelets may 
designate proteins as substrates for proteolysis by ubiquitination, as in nucleated 
cells. We determined whether platelets contained E1, E2, E3 enzymes that 
sequentially conjugate ubiquitin to target proteins. In order to ensure that we 
assessed only platelet proteins, we also isolated highly purified, negatively 
selected platelets that were essentially free of nucleated cells (less than 1 
monocyte in 109 platelets (Shashkin, Brown et al. 2008). Western blotting 
showed that these platelets contained the E1 activating enzyme UBE1, E2 and 
E3 ligases, and Rpn2 and the 11S -subunit of the 19S regulatory complex (Fig. 
2.2 A). 
 We used in vitro ubiquitination of exogenous p53, since platelets lack this 
transcription factor, to determine whether platelet UBE1 was functional. 
Incubation of recombinant p53 with recombinant E1 and appropriate recombinant 
E2 and E3 enzymes along with ubiquitin and ATP resulted in robust p53 
ubiquitination with formation of numerous slowly migrating adducts (Fig. 2.2 B). 
Substitution of a platelet lysate for recombinant E1 also promoted in vitro 
ubiquitination of p53, although the higher molecular weight ladder was less 
prominent than produced by recombinant E1 (Fig. 2.2 B). 
 We next determined whether endogenous platelet proteins were modified 
by ubiquitin. Western blotting with FK2 antibody that recognizes both mono- and 
poly-ubiquitin chains showed that the proteome of quiescent cells contained 
multiple ubiquitinated proteins (Fig. 2.2 C). The intensity of ubiquitination 
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increased after thrombin activation, although the pattern and position of the 
adducted bands was unaltered compared to control cells. ADP stimulation also 
increased ubiquitination of platelet proteins, but this primarily reflected an 
increase in modification of very slowly migrating proteins (Fig. 2.2 C). 
 We investigated whether inhibiting the platelet proteasome altered the 
amount of ubiquitinated proteins. Pretreatment with MG132 increased both the 
abundance and the levels of ubiquitinated proteins as detected with the anti-
ubiquitin antibody (Fig. 2.2 D). In fact, MG132 was significantly more effective 
than thrombin or ADP stimulation in enhancing decoration of the proteome with 
ubiquitin, and the combination of agonist stimulation and MG132 was not 
different from the effect of MG132 alone (Fig. 2.2 D). We observed a similar 
increase in ubiquitinated proteins after treatment with bortezomib (Fig. 2.2 E). 
Probing the platelet proteome with FK1 antibody that recognizes only poly-
ubiquitinated proteins revealed less abundant modification in unstimulated cells 
(Fig. 2.2 F). This was increased by agonist stimulation and was again greatly 
enhanced by MG132 treatment. Comparison of FK2 (Fig. 2.2 D) and FK1 (Fig. 
2.2 F) immunoblots showed distinct patterns of mono-and poly-ubiquitination of 
the platelet proteome. 
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Figure 2.2 Platelets contain a functional ubiquitination system 
 (A) Platelets contain components of ubiquitin-proteasome system. Immunoblots 
of platelet E1 activating enzyme, E2 and E3 conjugating enzymes, and 
proteasome regulatory cap proteins (n=3). (B) Platelet E1 is functional. Platelet 
lysates substituted for recombinant E1 and together with recombinant E2, E3, 
ubiquitin and ATP ubiquitinated recombinant p53 (n=3). (C) Agonist stimulation 
increases platelet proteome ubiquitination. Lysates of platelets stimulated with 
buffer, thrombin (thr) or ADP were immunoblotted with FK2 antibody against 
mono-and polyubiquitinated proteins (n=3). (D) MG132 increases proteome 
ubiquitination. Lysates of platelets, treated or not with MG132 were stimulated, or 
not, before immunoblotting with FK2 (n=3). (E) Both MG132 and bortezomib 
increases proteome ubiquitination. Western blot of MG132 or bortezomib treated 
platelet lysate over indicated times as probed with FK1 antibody (n=3). (F) 
MG132 increases poly-ubiquitination of platelet proteins (n=3). Western blotting 
of platelet lysates with FK1 antibody (n=3).  
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2.3.3 Filamin A is ubiquitinated, and truncated by the proteasome 
 Filamin A links the GPIb-IX-V complex to actin filaments of the 
cytoskeleton to modify cytoskeletal shape (Cunningham, Meyer et al. 1996). 
Filamin A was present in the soluble fraction of quiescent platelets as a 225 kD 
fragment of the 280 kDa native protein (Fig. 2.3 A). MG132 inhibition of the 
proteasome decreased the amount of this smaller band and increased the 
amount of intact Filamin A. Capture of ubiquitinated platelet proteins by a sushi 
domain column followed by immunoblotting using anti-Filamin A antibody showed 
that the fragment of Filamin A in quiescent cells was constitutively modified with 
ubiquitin (Fig. 2.3 B). This approach also showed that MG132 increased the 
amount of Filamin A ubiquitination, and increased the apparent size of the 
ubiquitinated Filamin A (Fig. 2.3 B). That Filamin A was ubiquitinated and that a 
larger, more extensively ubiquitinated protein accumulated after MG132 
treatment was confirmed by the converse experiment where Filamin A was 
immunoprecipitated from platelet lysates and then probed for ubiquitin (Fig. 2.3 
C) using FK2 antibody. The cytoskeletal protein Talin-1 participates in cell 
spreading, and similar experimental approaches of western blotting (Fig. 2.3 D), 
sushi domain capture of ubiquitin adducts (Fig. 2.3 E), and immunoblotting of 
captured Talin-1 for mono-and poly-ubiquitin chains (Fig. 2.3 F) showed that 
Talin-1 was present in the cytosol in a rapidly migrating, ubiquitinated form. 
Again, MG132 treatment increased its apparent size and ubiquitin content. 
 Coomassie blue staining of soluble proteins showed MG132 treatment did 
not alter overall platelet protein mass or composition, but there were two 
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abundant exceptions (Fig. 2.3 G). Two new, slowly migrating bands appeared in 
the soluble fraction of platelets treated with MG132. Mass spectrometry showed 
Filamin A to be present in the new band 1, and Talin-1 in bands 1 and 2 of the 
resolved soluble proteins, corresponding to the altered mobility detected by 
western blotting. 
 We used Tandem Mass spectrometry Tags (TMT)—chemically identical 
tags differentially substituted with heavy atoms that enable quantitative 
multiplexed analysis—to quantitatively compare the amount of Filamin A peptides 
in tryptic digests of control and MG132 treated platelets. Untreated (band 3) and 
MG132 treated (band 1) platelets were separately digested with trypsin, their 
primary amines exhaustively modified with isobaric TMT tags (m/z 126 and m/z 
127, respectively) before combined analysis by mass spectrometry. The peptides 
confirmed both bands contained Filamin A, and the tags showed the abundance 
of Filamin A tryptic peptides in band 1 and band 3 uniformly gave a m/z 126/127 
ratio of 1.9. This ratio plunged to 0.08 after the tryptic peptide containing residues 
1718-1745 (Fig. 2.3 H), demonstrating increased abundance of the full length 
protein after MG132 treatment. Chymotryptic digestion of band 3 isolated from 
control cells generated a distinct peptide map and selected reaction monitoring 
identified a new Filamin A peptide with S1746 as its amino terminus. This identifies 
the R1745 - S1746 bond as the site of cleavage in control cells, which maps into the 
unfolded hinge 1 region of Filamin A (Fig. 2.3 I). Notably, this cleavage is tryptic-
like, and is distinct from the previously determined calpain cut site (Gorlin, Yamin 
et al. 1990). 
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Figure 2.3 MG132 protects cytoskeletal protein cleavage 
 (A) Filamin A is ubiquitinated and its length increased by MG132. Western blot 
of Filamin A in the soluble fraction of platelets before and after MG132 exposure 
(n=3). (B) Ubiquitination and size of Filamin A are increased by MG132. Western 
blot of Filamin A in eluates of ubiquitinated platelet proteins captured with sushi 
columns [agarose beads conjugated to anti-ubiquitin antibody, (n=3)]. (C) Filamin 
A ubiquitination and size are increased by MG132. FK2 western blot of mono- 
and poly-ubiquitinated proteins immuoprecipitated with anti-Filamin A. (D) Talin-1 
is ubiquitinated and its size increased by MG132. Western blot of Talin-1 before 
and after MG132 exposure (n=3). (E) Ubiquitination and size of Talin-1 are 
increased by MG132. Talin-1 in ubiquitinated platelet proteins captured by sushi 
domain chromatography (n=3). (F) Talin-1 ubiquitination and size are increased 
by MG132. FK2 western blot of mono- and poly-ubiquitinated proteins 
immuoprecipitated by anti-Talin-1 (n=3). (G) MG132 increases high molecular 
weight proteins. Coomassie stained gel of resolved platelet cytoplasmic proteins. 
(H) Mass spectrometer determination of the mz 126/127 ratio of TMT-labeled 
peptides along the Filamin A sequence (n=2). (I) Pictogram of Filamin A 
structure. 
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2.3.4 Proteasome inhibition reduces cytoskeleton-dependent functions 
 Filamin A is a critical regulator of cytoskeletal structure and function, so 
we next tested the hypothesis that proteasomal inhibition alters platelet functions 
regulated by cytoskeletal dynamics, including GPIb function, microparticle 
generation, and clot retraction. 
 First, we imaged cytoskeletal dependent spreading by Total Internal 
Reflection Microscopy (TIRF) that detects only fluorophore closely opposed (≤ 
200 nm) to a glass matrix. Calcein-labeled platelets adhered over time after 
activation by thrombin with extension of filopodia followed by lamellipodia (video 
supplement) that resulted in adherent, spread cells (Fig. 2.4 A). In contrast, while 
MG132-treated cells adhered and spread after thrombin stimulation, they did so 
with less frequency, rapidity, and ultimately were less splayed (Fig. 2.4 B).  
 Stimulated platelets release pro-thrombotic microparticles from their 
surface that depends on cytoskeletal rearrangement after stimulation (Morel, 
Jesel et al. 2011). Thrombin induced a ~6 fold increase in microparticle shedding 
(Fig. 2.4 C and D), which was significantly reduced by pre-treating the platelets 
with either MG132 (Fig. 2.4 C) or bortezomib (Fig. 2.4 D). MG132 also blocked 
microparticle release from LPS-stimulated platelets (Fig. 2.4 E). The majority of 
these particles express phosphatidylserine on their surface which can be 
detected by annexin V staining. Both MG132 (Fig. 2.4 F) and bortezomib (Fig. 
2.4 G) reduced thrombin induced increase in annexin V positive microparticle 
shedding. MG132 also suppressed LPS induced shedding of annexin V positive 
microparticles (Fig. 2.4 H). The surface of these annexin V positive microparticles 
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is ~50-100 fold more thrombotic than even the activated platelets (Sinauridze, 
Kireev et al. 2007) and they promote thrombosis through tissue factor pro-
coagulant activity (Fig. 2.4 I), which MG132 significantly inhibited. 
 Cytoskeletal rearrangement retracts newly formed thrombi, promoting 
wound repair (Cheresh, Leng et al. 1999; Grinnell 1999). Stimulation of platelets 
with thrombin induced rapid formation of a thrombus that then consolidated over 
time (Fig. 2.4 J). MG132 interfered with this process, ultimately decreasing 
retraction by 60%.  
87 
 
88 
 
Figure 2.4 MG132 suppresses stimulated spreading, microparticle 
shedding, and clot retraction  
(A) MG132 disturbs thrombin stimulated adhesion and spreading. Interaction of 
control or thrombin (thr, 0.025 U) stimulated platelets with a glass substrate were 
imaged by Total Internal Reflection Microscopy after 5 min (n=3) (scale bar = 10 
µM). (B) Platelet area after MG132 treatment. Platelet area in Panel A was 
quantified by Imagepro plus software (n=3; ***p≤ 0.001). (C) Microparticle 
shedding by platelets stimulated with 0.2 U thrombin with or without MG132 (n=3; 
**p≤ 0.01). (D) Bortezomib (n=3; *p≤ 0.05). (E) Microparticle shedding by platelets 
pretreated with or without MG132 and stimulated with lipopolysaccharide (LPS, 
n=3; *p≤ 0.05). (F) Proteasome inhibitors suppress agonist-induced shedding of 
procoagulant microparticles. Annexin V positive microparticle shedding by 
platelets stimulated with 0.2 U thrombin with or without MG132 (n=3; *p≤ 0.05). 
(G) Bortezomib (n=3; *p≤ 0.05). (H) Annexin V positive microparticle shedding by 
platelets stimulated with lipopolysaccharide (LPS, n=3; *p≤ 0.05). (I) Tissue factor 
procoagulant activity in platelet microparticles stimulated with 0.2 U thrombin with 
or without MG132  (n=3; *p≤ 0.05). (J) MG132 represses clot retraction. Ratio of 
the image surface area of images of thrombin-induced clots over time (n=3; **p≤ 
0.01). 
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2.3.5 Proteasome inhibition selectively reduces aggregation stimulated by 
low concentrations of thrombin 
 Thrombin stimulates platelets by cleaving surface PAR1 (protease-
activated receptor 1) to create a self stimulatory terminal SFLLRN peptide, 
(Coughlin and Camerer 2003) but at low concentrations thrombin activates 
platelets through the high affinity GPIb-IX-V receptor (Greco, Tandon et al. 
1996). Both MG132 and bortezomib reduced homotypic platelet aggregation at 
low concentrations of thrombin (Fig. 2.5 A). 
 The effect of proteasome inhibitors was on the high affinity GPIb-IX-V 
complex because the SZ2 antibody against GPIb (CD42b) fully blocked 
aggregation at a low concentration of thrombin (Fig. 2.5 A). The PAR1 agonist 
SFLLRN induced platelet aggregation that was completely blocked by a PAR1 
specific antagonist (RWJ56110, Fig. 2.5 B). However, neither MG132 (Fig. 2.5 B) 
nor bortezomib (not shown), suppressed aggregation induced by SFLLRN. 
Aggregation induced by a low, submaximal amount of SFLLRN also was 
unimpeded by MG132 (Fig. 2.5 C). Thus, PAR-1 agonist induced platelet 
aggregation is proteasome independent. MG132 also failed to affect aggregation 
induced by AYPGFK stimulation of PAR 4 (Fig. 2.5 D). Furthermore, neither 
MG132 nor bortezomib inhibited platelet aggregation stimulated by a higher 
thrombin concentration that acts through PAR1 (Fig. 2.5 E). The modifiers SZ2, 
MG132, or RWJ56110 by themselves did not induce aggregation (Fig. 2.5 F). 
 Proteasome protease activity was required by the high affinity thrombin 
receptor because epoxomicin inhibited platelet aggregation by low thrombin 
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concentrations (Fig. 2.5 G) and this inhibition was statistically significant (Fig. 2.5 
H). Epoxomicin is a fungal metabolite, structurally unrelated to either MG132 or 
bortezomib, that specifically inhibits proteasome protolysis without inhibiting 
calpain, trypsin, chymotrypsin, or cathepsin B at concentrations 50-times higher 
than we used for blocking platelet aggregation (Meng, Mohan et al. 1999). 
The GPIb-IX-V complex is displayed on the surface of quiescent cells, and is 
down regulated after thrombin stimulation (Michelson, Ellis et al. 1991). I found 
both MG132 (Fig. 3.5 I) and bortezomib (Fig. 3.5 J) stabilized the GPIb-IX-V 
complex on the surface of stimulated cells, and actually enhanced surface GPIb 
(CD42b) expression. This surface retention of the receptor in platelets treated or 
not with proteasome inhibitors is significant (Fig. 2.5 K).   Ristocetin increases the 
affinity of GPIb for VWF, agglutinating unactivated cells, and pre-treatment of 
quiescent platelets with MG132 (Fig. 2.5 L) or bortezomib (Fig. 2.5 M) reduced 
ristocetin induced platelet agglutination. Thus despite the increased surface 
expression of the GPIb-IX-V complex after proteasome inhibition, the complex is 
less able to interact with VWF than in control platelets. 
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Figure 2.5 MG132 reduces aggregation in response to low dose thrombin, 
and prevents GP1bα downregulation 
(A) MG132 and bortezomib suppress platelet aggregation induced through the 
high affinity thrombin receptor, GP1b-IX-V. Aggregation induced by 0.025 U 
thrombin (thr) was reduced by MG132 and bortezomib (n=3). (B) MG132 failed to 
reduce aggregation stimulated by the PAR1 (protease-activated receptor 1) 
agonist peptide SFLLRN (n=3). (C) MG132 (30 µM) pretreatment minimally 
reduces aggregation stimulated by low concentrations of the PAR1 agonist 
peptide SFLLRN (n=3). (D) MG132 failed to reduce aggregation stimulated by 
the PAR4 agonist peptide AYPGKF at both 200 µM and 150 µM concentrations 
(n=3). (E) Neither MG132 nor bortezomib block aggregation from thrombin 
activation of PAR1. Platelet aggregation by 0.1 U thrombin with or without SZ2 
antibody (n=3). (F) GP1bα or PAR1 inhibition alone does not induce aggregation 
(n=3). (G) Aggregation induced by 0.025 U thrombin (thr) was reduced in 
platelets pretreated with 1 µM epoxomicin for 30 min (n=3). (H) Quantitative 
representation of percentage maximum (Max) aggregation (n=3; **p≤ 0.01). (I) 
MG132 repressed stimulated GPIbα down regulation. Flow cytometry of surface 
CD42b (GPIbα) expression on platelets treated or not with MG132 and 
stimulated or not with 0.025 U thrombin (n=3). (J) Bortezomib repressed surface 
GPIbα down regulation. Flow cytometry of GPIbα expression on control and 
thrombin stimulated platelets (n=3). (K) Mean fluorescence intensity (MFI) of 
surface CD42b (GPIbα) expression on platelets treated either with MG132 or 
bortezomib and stimulated or not with 0.025 U thrombin (n=3; *p≤ 0.05). (L) 
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MG132 suppressed ristocetin induced agglutination. Quiescent platelets 
pretreated or not with MG132 were agglutinated with ristocetin (n=3). (M) 
Bortezomib suppressed ristocetin induced agglutination. Quiescent platelets 
pretreated or not with bortezomib were agglutinated with ristocetin (n=3).  
2.4 Discussion 
  Multiple myeloma is associated with an increased incidence of venous 
(Srkalovic, Cameron et al. 2004; Zangari, Elice et al. 2007; Kristinsson, Fears et 
al. 2008) and arterial (Libourel, Sonneveld et al. 2010) thrombotic disease, and 
bortezomib therapy suppresses these thrombotic states (Zangari, Guerrero et al. 
2008). Platelets display proteasome chymotryptic activity that is greatly 
stimulated by soluble agonists (Nayak, Kumar et al. 2011). Additionally, 
bortezomib represses ADP-induced aggregation (Avcu, Ural et al. 2008) and 
platelets isolated from patients receiving bortezomib are hyporesponsive to other 
stimuli (Zangari, Guerrero et al. 2008; Shen, Zhou et al. 2011). A second 
proteasome inhibitor, PSI, suppresses thrombosis in hypertensive animals 
(Ostrowska, Wojtukiewicz et al. 2004). 
 I extend these observations by showing that platelets contain an intact and 
functional ubiquitin/proteasome system that participates in agonist stimulated 
responses, especially those aided by cytoskeletal rearrangement. I found that 
inhibition of the proteasome’s proteolytic activity reduced thrombosis at sites of 
oxidative damaged to murine carotid arterial walls. Since MG132 was introduced 
into the circulation in this experiment, protection need not have been a direct 
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effect of MG132 on platelet function, but the target of MG132 in platelets is in fact 
the proteasome. I treated purified platelets with MG132 ex vivo, washed them, 
and then transfused these cells into mice rendered thrombocytopenic by prior 
gamma irradiation. This platelet-specific exposure to MG132 interfered with the in 
vivo function of platelets because MG132 treated platelets were deficient in their 
occlusion of a FeCl3-damaged carotid artery. Remarkably, this ex vivo exposure 
exactly mimicked systemic exposure to MG132. This establishes a role for the 
platelet proteasome in thrombosis. 
 Platelets contained a functional ubiquitin system that modified cellular 
proteins to mark them as proteasome substrates. The proteome of quiescent 
platelets contained numerous ubiquitin-protein conjugates whose adduction was 
increased upon stimulation, consistent with the prior observation that collagen 
activation stimulates ubiquitination of platelet Syk kinase(Dangelmaier, Quinter et 
al. 2005) through the E3 ligase Cbl-b.(Daniel, Dangelmaier et al. 2010) Two of 
the proteins decorated with ubiquitin in quiescent platelets were Filamin A and 
Talin-1. Agonist stimulation modestly increased the amount of ubiquitin esterified 
in the platelet proteome, but blockade of the proteasome was far more effective 
than agonist stimulation for this, with the result that heavily ubiquitinated Filamin 
A, and Talin-1 accumulated in the cytoplasm of cells with diminished proteasome 
proteolytic activity. 
 Filamin A is organized into an actin-binding domain (ABD), 24 tightly 
compacted FERM immunoglobulin-like repeats connected with short linking 
sequences, and two unstructured hinge regions. Cytoplasmic Filamin A migrated 
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more quickly than the intact protein during gel electrophoresis, suggesting it 
primarily was a fragment. Quantitative comparison of tryptic peptides using 
tandem mass spectrometry tags showed that MG132 protected Filamin A from 
cleavage to the smaller 225 kDa fragment. Identification of Filamin A peptides 
present only after MG132 treatment and identification of the new amino terminal 
peptide after chymotryptic digestion by multiple reaction monitoring showed 
cleavage of the Filamin A protein occurred between R1745 and S1746. This is in 
a hinge region that is not compacted into FERM domains. Cleavage at this site is 
distinct from the previously determined calpain cut site, (Gorlin, Yamin et al. 
1990) and shows the protease was tryptic since it occurred after an arginine 
residue. The proteasome subunits functionally interact with one another 
(Kisselev, Callard et al. 2006) to degrade proteins to amino acids and small 
peptides, but the proteasome also processes large proteins to functional 
fragments, as shown by NF-κB p105 proteolysis to the p50 transcription factor 
(Rape and Jentsch 2002). We now identify the longer unstructured Filamin A 
loop as another site of limited proteasome proteolysis, but our data is associative 
so we cannot ascribe this proteolysis as causal in MG132 inhibition of platelet 
adhesion or spreading.  
 Platelets pretreated with MG132 or bortezomib aggregated less in 
response to low concentrations of thrombin. Adhesion, spreading, microparticle 
shedding, and the ability to generate the force to retract formed clots was also 
reduced by proteasome inhibition. Cytoskeletal interactions aid microparticle 
shedding from stimulated platelets, and proteolysis by activated calpain (Fox, 
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Austin et al. 1991; Basse, Gaffet et al. 1994) and caspase-3 (Shcherbina and 
Remold-O'Donnell 1999) promote microparticle shedding through cytoskeletal 
proteolysis (Basse, Gaffet et al. 1994). The reduction of microparticle shedding is 
additionally revealing because MG132 suppressed shedding after stimulation by 
LPS activation of TLR4, thrombin activation of PAR1, and ADP activation of 
P2Y12. So, MG132 interference with stimulated platelet function is not restricted 
to GPIb-IX-V activation by thrombin. 
 We establish that platelets, like nucleated cells, express a functional 
ubiquitin/proteasome system that enables them to ubiquitinate their proteome. 
This decoration increases upon stimulation, and modulates an array of 
responses from several receptors that all engage the cytoskeleton. The 
cytoskeletal proteins Filamin A and Talin-1 are targets of ubiquitination, and 
proteasome mediated proteolysis. The ubiquitin/proteasome system of platelets 
affects their response to thrombotic stimuli, and proteasome inhibition effectively 
delayed arterial thrombosis. Bortezomib is already in clinical practice for multiple 
myeloma and mantle cell lymphoma so elucidation of its anti-platelet activity 
defines a new salutary function of these inhibitors.  
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2.5 Chapter summary 
 These data demonstrate that platelets, like nucleated cells, express a 
functional ubiquitin/proteasome system that enables them to modify their 
proteome by mono- and poly-ubiquitination. Proteasome inhibition increased 
ubiquitin decoration of cytoskeletal proteins Filamin A and Talin-1 and increased 
platelet content of soluble intact filamin A. Proteasome inhibition by MG132 
suppressed stimulated platelet spreading as well as clot retraction. Proteasome 
inhibition reduced platelet aggregation by low thrombin concentrations and 
ristocetin-stimulated agglutination through the GPIb-IX-V complex. The effects of 
proteasome inhibitors were not confined to a single receptor as both MG132 and 
bortezomib suppressed thrombin-, ADP-, and LPS-stimulated microparticle 
shedding. Systemic MG132 strongly suppressed formation of occlusive, platelet-
rich thrombi in FeCl3-damaged carotid arteries. Importantly, this is due to the 
direct effect of proteasomal inhibition on platelets as transfusion of platelets 
treated ex vivo with MG132 and washed prior to transfusion into 
thrombocytopenic mice also reduced carotid artery thrombosis. 
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Chapter III 
Unmasking platelet reactivity through deubiquitination 
3.1 Introduction 
 Platelet activation underlies thrombotic cardiovascular disease that is 
responsible for significant disability and death in the developed world (Davi and 
Patrono 2007; Jackson 2011).  Platelet activation is transduced from the 
proteome delivered to platelets as they bud from megakaryocytes during 
thrombopoiesis, augmented by limited de novo protein synthesis (Zimmerman 
and Weyrich 2008). Platelets additionally contain a functional ubiquitin-
proteasome system that targets proteins to the proteasome for degradation by 
decorating platelet proteins both with single molecules of the 8 kDa ubiquitin 
protein and by chains of polymerized ubiquitin (Gupta, Li et al. 2014). 
Polyubiquitin chains assembled by conjugation to any of the seven lysines of 
ubiquitin alter protein degradation, intracellular trafficking, or protein recognition 
to participate in a diverse range of cellular processes from morphogenesis to 
autophagy to intercellular interactions (Kulathu and Komander 2012). 
Correspondingly, proteasome proteolysis enhances platelet aggregation,  
 
99 
 
adhesion, and microparticle shedding (Gupta, Li et al. 2014). 
 Post-translational modification by covalent ligation with ubiquitin is 
dynamic with six families of evolutionarily conserved deubiquitinases hydrolyzing 
these mono- and polymeric ubiquitin adducts (Fraile, Quesada et al. 2012). 
Deubiquitinase inhibitors alter a range of cellular functions with therapeutic 
potential (Colland 2010), as anticipated from the range of processes employing 
ubiquitin adduction. The general deubiquitinase inhibitor PR619 (Altun, Kramer et 
al. 2011) promotes autophagy, protein aggregation, and the unfolded protein 
response in nucleated cells (Seiberlich, Goldbaum et al. 2012; Seiberlich, 
Borchert et al. 2013). A small molecule inhibitor of E1 ubiquitin activating 
enzyme, PYR41 (Yang, Kitagaki et al. 2007), suppresses arachidonate-
stimulated adhesion and migration of tumor cells on a collagen surface (Ray, 
Rogers et al. 2010), angiotensin II-mediated dendritic cell activation (Chen, Meng 
et al. 2014), and NF-κB activation in tumor cells (Yang, Kitagaki et al. 2007). 
However, it also leads to accumulation of ubiquitinated proteins ex vivo and in 
vitro by inhibiting deubiquitinases (Kapuria, Peterson et al. 2011), allowing 
ubiquitin-modified proteins to accumulate. In the context of this work I find PYR41 
is a general DUB inhibitor independent of a role as an  E1 inhibitor in platelets.   
 Recently, a small molecule inhibitor, b-AP15, was identified that 
specifically inhibits proteasome-associated deubiquitinase activity independent of 
numerous cytoplasmic deubiquitinases (D'Arcy, Brnjic et al. 2011). The 
proteasome-associated deubiquitinase activity is contributed by  three 
deubiquitinase enzymes: Rpn11, USP14 and UCHL5, associated with the 
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regulatory subunit of proteasome (Lam, DeMartino et al. 1997; Borodovsky, 
Kessler et al. 2001; Verma, Aravind et al. 2002). b-AP15 displays potent anti-
tumor activity both in vivo and in vitro and is highly specific  for USP14 and 
UCHL5, showing no inhibitory activity towards non-proteasomal deubiquitinases 
(D'Arcy, Brnjic et al. 2011). b-AP15 also reduced viability of multiple myeloma 
cells and overcomes the resistance to the proteasome inhibitor bortezomib (Tian, 
D'Arcy et al. 2014).      
 Platelets express a number of deubiquitinases (Burkhart, Vaudel et al. 
2012), but the potential function of these enzymes in platelets is unstudied. I 
determined whether ubiquitination of the platelet proteome was dynamic and 
subject to deubiquitination to recover free ubiquitin and remodel existing 
polymeric ubiquitin chains. I find platelets contain several deubiquitinases that 
regulate platelet thrombotic aggregation and activation ex vivo, and that 
deubiquitinase inhibition reduced occlusive thrombosis in vivo. These results 
suggest modulation of deubiquitinase activity is a potential new approach to anti-
platelet therapy. 
3.2 Materials and Methods 
3.2.1 Chemicals and reagents 
 Chemicals and reagents were purchased from: sterile ﬁltered HBSS and 
sterile tissue culture plates (Falcon Labware); endotoxin-free human serum 
albumin (25% human albumin solution, Baxter Healthcare); PYR41 (Biogenova), 
PR619 (Life Sensors), b-AP15 (Sigma-Aldrich); polyubiquitin chains (Ub 2-7) 
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K48/K63 linked, HA-Ubiquitin-Vinyl Sulfone (Boston Biochem); anti-ubiquitin 
antibody (P4D1; Santa Cruz Biotechnology, Inc.); anti-HAUSP antibody (Bethyl 
Laboratories); anti-Ub K48 antibody (Millipore); Calcein-AM (Molecular Probes®, 
Life Technologies); DUB-GLOTM Protease Assay kit (Promega); anti-Akt, anti-
pAkt ser473, anti-pAkt thr308 and anti-pPTEN antibody (Cell Signaling). Other 
chemicals were from Sigma-Aldrich or Biomol Research Laboratories.  
3.2.2 Platelet preparation 
 Human blood was drawn into acid-citrate-dextrose and centrifuged (200 × 
g, 20 min) without braking to obtain platelet-rich plasma in a protocol approved 
by the Cleveland Clinic Institutional Review Board. Purified platelets were 
prepared as stated (Brown and McIntyre 2011). Briefly, platelet-rich plasma was 
filtered through two layers of 5-μm mesh (BioDesign) to remove nucleated cells 
and recentrifuged (500 × g, 20 min) in the presence of 100 nM PGE1. The pellet 
was resuspended in 50 ml PIPES/saline/glucose (5 mM PIPES, 145 mM NaCl, 4 
mM KCl, 50 μM Na2HPO4, 1 mM MgCl2, and 5.5 mM glucose) containing 100 nM 
PGE1. These cells were centrifuged (500 × g, 20 min) and recovered platelets 
were centrifuged again before resuspension in 0.5% human serum albumin in 
HBSS.  
3.2.3 Western blotting  
 Washed platelets (4 X 108/ml) were treated 25 µM PYR41, 30 µM PR619, 
10 µM b-AP15, or buffer for 30 min before platelets were pelleted (2000 X g, 10 
min) and lysed using radioimmunoprecipitation assay (RIPA) lysis buffer [150 
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mM NaCl, 25 mM Tris (pH 7.6), 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 
0.5% deoxycholate, 2 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 10 
mM sodium fluoride, 100 µM phenylmethylsulfonyl fluoride (PMSF), 1 µg/mL 
pepstatin, and 10 µg/mL leupeptin]. Samples were kept on ice for 30 min with 
occasional vortexing to ensure complete lysis before centrifugation (21,000 x g, 
10 min). Reducing SDS sample buffer was added to the resulting supernatants 
before the proteins were resolved by SDS-PAGE. 
3.2.4 Deubiquitination Assay and Ubiquitin chain disassembly 
 DUB-Glo™ protease assay system (Promega) assayed hydrolysis of 
luminogenic substrates for the deubiquitinating enzymes (DUBs). Washed 
platelets (4 X 108/ml) were pretreated with or without 25 µM PYR41 or 30 µM 
PR619 for 30 min, pelleted and lysed in ice cold DUB buffer (50 mM Tris-HCl, pH 
7.5, 0.1% NP-40, 5 mM MgCl2, 150 mM NaCl, 10 mM DTT, 1 mM sodium 
orthovanadate, 10 mM sodium fluoride, 100 µM PMSF, 1 µg/ml pepstatin, and 10 
µg/ml leupeptin) and incubated with luminogenic substrate for 30 min before 
luminescence was measured. Ubiquitin chain disassembly was assessed by 
incubating recombinant polymerized K48 or K63 linked-ubiquitin chains with 
lysates (20 μg) from untreated, PYR41-(25 µM) or PR619-(30 µM) treated 
platelets for 30 min at 30 ºC followed by boiling in reducing sample buffer and 
resolution by SDS-PAGE. The extent of chain disassembly was assessed by 
western blotting using P4D1 antibody to recognize both free and polymeric 
ubiquitin. 
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 Activity-based deubiquitinase labeling used washed platelets (4 X 108/ml) 
treated or not with 25 µM PYR41 or 30 µM PR619 for 30 min before lysis in ice 
cold DUB buffer. Lysates (20 µg) cleared by centrifugation were incubated with 
200 ng HA-Ubiquitin vinyl sulfone (Boston Biochem) for 30 min at 30 ºC, boiled in 
reducing sample buffer, and resolved by SDS-PAGE. Proteins were transferred 
to nitrocellulose membranes and immunoblotted with anti-HA antibody to detect 
covalently labeled proteins. 
3.2.5 In vivo thrombosis 
 Twelve week old C57B/6 mice were anesthetized with ketamine (90 
mg/kg)/xylazine (15 mg/kg) and the right jugular vein and the left carotid artery 
were exposed via a middle cervical incision. Platelets were labeled by injecting 
100 μl of rhodamine 6G (0.5 mg/ml) in saline into the right jugular vein. PYR41 
(25 µM in DMSO; 4.7 mg/kg) or DMSO vehicle (10.5 µl) was added to the above 
solution, and the drug was allowed to circulate for 15 min before FeCl3 injury (Li, 
Febbraio et al. 2010; Li, McIntyre et al. 2013). Thrombosis was induced in the left 
carotid artery by stripping the adventitia and placing a piece of black plastic 
under the vessel to reduce background fluorescence. A 1 X 2 mm piece of filter 
paper saturated with 7.5% FeCl3 was applied to the carotid artery for 1 minute, 
the filter paper was removed, and the vessel rinsed with saline. Fluorescent 
thrombus formation was observed in real-time under a water immersion objective 
at 10 X magnification. Time to occlusive thrombosis was determined offline using 
video images captured with a QImaging Retigo Exi 12-bit mono digital camera 
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(Surrey, Canada) and Streampix version 3.17.2 software (Norpix, Montreal, 
Canada). The end points were set as either cessation of blood flow for >30 
seconds or no occlusion after 30 minutes (three times longer than the average 
occlusion time), in which case the time was recorded as 30 minutes for statistical 
comparison. 
3.2.6 In vitro thrombus formation: 
 Microfluidics experiments were performed using the Cellix Microfluidics 
System (Cellix Ltd., Dublin, Ireland). Each micro channel of a Vena8 Fluoro+ 
biochip was coated with 15 µl of type 1 collagen (150 µg/ml) and the biochip was 
then placed in a humidified box, and incubated overnight at 4ºC. Each channel of 
the Vena8Fluoro+ biochip was washed with 1X PBS using the Mirus Nanopump 
before placing the biochip on the microscope stage. Images were collected using 
an HC Plan Apo 20X/0.7NA lens was on a Leica DMI6000 inverted microscope 
equipped with an environmental chamber and a Hamamatsu ImagEM cooled 
CCD camera. Whole blood collected from healthy volunteers was fluorescently 
tagged with Calcein-AM and was pretreated with or without 25 µM PYR41 or 30 
µM PR619 for 30 min. After the incubation, blood was drawn through the channel 
at a shear rate of 67.5 dynes for 3 minutes. Images of platelets adhering to the 
collagen coating were captured every 2 seconds during that time. At the end of 
the experiment, the tube containing the blood was removed and the 1X PBS in 
the biochip reservoir was drawn through the channel at 2.5 dynes. Ten images 
were captured along the length of the channel during that time. 
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3.2.7 Flow cytometry  
 Platelet rich plasma (PRPs, 2 X 108/ml) was pretreated with either 25 µM 
PYR41, 30 µM PR619, or 10 µM b-AP15 for 15 min. After pretreatment, PRPs 
were incubated with 25 µM ADP and were stained simultaneously with PAC1-
FITC or CD62P-PE and isotype control antibody (BD Biosciences) for 20 min 
room temperature. Washed platelets (2 X 108/ml) were pretreated with 25 µM 
PYR41, 30 µM PR619, 10 µM b-AP15, or buffer for 30 min and then were 
incubated with 0.2 U thrombin or 100 ng convulxin. These cells were then stained 
simultaneously with PAC1-FITC and CD62P-PE or with isotype control for 20 min 
room temperature.  The samples were then analyzed using flow cytometery.  
3.2.8 Total internal reflection fluorescence (TIRF) microscopy  
 Washed platelets (2 X 108/ml) were labeled with calcein-AM for 30 min 
and were incubated  with 25 µM PYR41, 30 µM PR619, or buffer for 30 min 
before addition onto a drop of 0.2 U thrombin placed in a glass bottomed 
microwell (MatTek) dish. Imaging was performed at 100X with a 1.46 N.A. 
objective in a Leica AM TIRF MC System (Leica Microsystems, Wetzlar, 
Germany) equipped with an ImageEM C9100-13 EMCCD camera (Hamamatsu, 
Bridgewater, N.J). The 488 nm 10-mW diode laser was used for excitation and 
the penetration depth was set to 70 nm. Within 10 seconds of being placed on 
the stage, the sample was focused and a time-lapse series was initiated to 
collect images every 3 seconds for 5 minutes. At the end of the series, five static 
images were collected in both TIRF and differential interference contrast (DIC)  
modes of five different fields in the sample.  
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3.2.9 Aggregation 
 PRPs (2 X 108/ml) were pretreated with either 25 µM PYR41, 30 µM 
PR619,  or 10 µM b-AP15 for 15 min. After pretreatment, PRPs were stimulated 
with 5 µM ADP (Chronolog). Washed platelets (2 X 108/ml) were pretreated with 
either 25 µM PYR41, 30 µM PR619, or 10 µM b-AP15 for 30 min before 
stimulation with 0.2 U thrombin, 2 µg/ml Collagen or 100 ng convulxin. Platelet 
aggregation was measured by transmittance (Chronolog) with stirring (900 rpm).  
3.2.10 Expression of data and statistics 
 All experiments were performed at least three times with cells from 
different donors, and all assays were performed in triplicate. The standard errors 
of the mean from all experiments are presented as error bars. Figures and 
statistical analyses were generated with Prism4 (GraphPad Software). A value of 
p≤ 0.05 was considered statistically significant. 
3.3 Results 
3.3.1 Deubiquitination of the platelet proteome promotes thrombosis  
 Arterial thrombosis is modeled in vivo by FeCl3-induced injury of the wall 
of murine carotid arteries that leads to rapid formation of a platelet-rich occlusive 
barrier at the site of injury (Li, Febbraio et al. 2010; Li, McIntyre et al. 2013). 
Typically, complete cessation of flow through the artery of DMSO injected mice 
occurs 12 min after the brief exposure to ectopic FeCl3 (Fig. 3.1 A). Disruption of 
ubiquitin metabolism by intravenous injection of PYR41 15 min prior to vessel 
injury significantly lengthened the time to occlusion to 26 min.  
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 The occlusive thrombus formed in FeCl3-damaged carotid arteries is 
almost exclusively formed by platelet accretion, so I determined whether platelets 
contained deubiquitinase activity that was inhibited by PYR41. Deubiquitinase 
enzymes are specifically covalently adducted during hydrolysis of HA-tagged 
ubiquitin vinyl sulfone (Borodovsky, Kessler et al. 2001), and this mechanism-
based inhibitor modified a number of platelet proteins (Fig. 3.1 B). PYR41 and a 
structurally unrelated deubiquitinase inhibitor PR619 decreased catalytic labeling 
of all platelet deubiquitinases. Direct measurement of ubiquitination hydrolytic 
activity showed platelet lysates contain deubiquitinase enzymatic activity, and 
that both PYR41 and PR619 showed platelets have active deubiquitinases and 
these compounds are equally effective in inhibiting them (Fig. 3.1 C). 
 The soluble proteome of quiescent platelets contains numerous ubiquitin 
conjugated proteins (Fig. 3.1 D), primarily with slow mobility during 
electrophoresis. Exposing platelets to either PYR41 or the PR619 deubiquitinase 
inhibitor for 30 min prior to lysis increased poly-ubiquitination of these soluble 
platelet proteins. The pattern of ubiquitinated proteins after either PYR41 or 
PR619 treatment recapitulated that of quiescent platelets, so platelets rapidly and 
continuously cycle ubiquitin onto select proteins. 
 Deubiquitinase enzymes are selective for ubiquitin chain linkages (Fraile, 
Quesada et al. 2012). Lysates from PYR41- or PR619-treated platelets showed 
limited disassembly of K48- linked (Fig. 3.1 E) and only minor effect on K63-
linked (Fig. 3.1 F) poly-ubiquitin chains compared to lysates from untreated 
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platelets. This limited chain disassembly may account for the accumulation of 
ubiquitin conjugates of high molecular weight observed in Fig. 3.1D.  
109 
 
110 
 
Figure 3.1 Platelets express functional deubiquitinases that promote 
thrombosis  
(A) Deubiquitinase inhibitor, PYR41 prolongs the time to vascular occlusion. Mice 
were injected with PYR41 or DMSO and thrombosis was induced 15 min later as 
described in "Methods". Time to complete cessation of blood flow in the murine 
carotid artery was determined using intravital microscopy (n=5 experimental, 3 
control; **p≤ 0.01). (B) Platelets contain several deubiquitinases. Western blot of 
anti-HA antibody after active-site–directed labeling of deubiquitinases with HA- 
tagged Ub-vinylsulfone in platelet lysates from washed platelets treated with or 
without PYR41 or PR619 (n=3). (C) The isopeptidase  activity of platelet 
deubiquitinases was assayed using a luminogenic substrate in the lysates of 
untreated and PYR41 or PR619 treated platelets (n=3; *p≤ 0.05). (D) PYR41 or 
PR619 pretreatment increases ubiquitination of platelet proteome. Immunoblot of 
platelet lysates, treated or not with PYR41 or PR619, probed with anti-ubiquitin 
antibody (P4D1, n=3). PYR41 or PR619 pretreatment limits hydrolysis of  (E) 
Lysine48- linked and (F) Lysine63- linked heptameric chain as detected by 
western blotting with anti-ubiquitin antibody (P4D1, n=2). 
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3.3.2 Deubiquitinase inhibitors suppress platelet adhesion to collagen 
under shear flow  
 Deubiquitinase inhibition in platelets reduced hydrolysis of ubiquitin chains 
and caused accumulation of ubiquitinated proteins, indicating that the ubiquitin 
cycling is affected by the inhibitors and that deubiquitinase inhibition directly 
alters platelet function to reduce adhesion to collagen exposed in injured arteries. 
To test this, I examined platelet adhesion during the flow of whole blood through 
a collagen-coated microfluidic channel that generates high shear. Fluorescently 
labeled platelets in whole blood were immobilized along the chamber, as shown 
in a typical video frame captured at the distal end of the chamber after 3 min of 
flow (Fig. 3.2 A). Preincubating cells with either PYR41 or PR619 reduced the 
number of platelets adhering in the collagen-coated well by 80% (Fig. 3.2 B). 
This outcome shows the adhesive phenotype of activated platelets depends on 
rapid deubiquitination of their proteome. 
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Figure 3.2 Deubiquitinase inhibitors suppressed in vitro thrombosis 
(A) PYR41 or PR619 pretreatment blocked platelet adhesion to collagen at high 
shear. Calcein-AM labeled blood, treated or not with PYR41 or PR616, was 
perfused over immobilized type 1 collagen fibrils (150 µg/ml) at 67.5 dyne/cm2 for 
3 min. Images are representative fields taken from three independent 
experiments that yielded similar results (n=3). (B) Area of platelet attachment 
after PYR41 or PR619 treatment. Platelet area in panel A was quantified by 
ImagePro plus software and results are plotted as area of platelet adhesion in 
square microns (n=3; ***p≤ 0.001). 
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3.3.3 Stimulated homotypic platelet aggregation, adhesion, and spreading 
are suppressed by deubiquitinase inhibitors 
 Washed human platelets aggregated in response to thrombin (Fig. 3.3 A), 
ADP (Fig. 3.3 B), or collagen (Fig. 3.3 C). Pre-incubation with either PYR41 or 
PR619 suppressed aggregation in response to each of these agonists. Neither 
compound alone promoted aggregate formation (Fig. 3.3 D), but inhibition by 
each deubiquitinase inhibitor was statistically significant and the inhibition by the 
two deubiquitinase inhibitors was equivalent (Figs. 3.3 E-G). 
Outside-in signaling as platelets interact with a glass substrate induces 
cytoskeletal rearrangement, extension of filopodia and lamellapodia. Thrombin 
stimulation enhances these responses captured by total internal reflection 
microscopy (Fig. 3.3 H). Both PYR41 and PR619 abolish the adhesion and 
spreading of unstimulated platelets, while greatly reducing these responses after 
thrombin stimulation (Fig. 3.3 I). 
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Figure 3.3 Deubiqutinase inhibition reduced platelet response to agonists   
 (A) PYR41 or PR619 pretreatment attenuated thrombin (thr)- (B) ADP- and (C) 
collagen-induced aggregation. (D) Neither PYR41 nor PR619 stimulated platelet 
aggregation in the absence of agonists. (E) PYR41 or PR619 imposed a 
reduction in thrombin (thr)- (F) ADP- and (G) collagen-induced aggregation is 
statistically significant (n=3; ***p≤ 0.001). (H) PYR41 or PR619 reduced thrombin 
stimulated adhesion and spreading. Interaction of control or thrombin stimulated 
(thr; 0.2 U) platelets with a glass substrate was imaged by total internal reflection 
microscopy after 5 min (n=3). (I) Platelet area after PYR41 or PR619 treatment. 
Platelet surface area in panel (A) was quantified by Imagepro plus software (n=3; 
***p≤0.001). 
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3.3.4 Agonist activation of glycoprotein αIIbβ3 is reduced by deubiquitinase 
inhibition  
 Agonist stimulation alters the conformation of the platelet β3 integrin of 
glycoprotein αIIbβ3 to enhance platelet-platelet and platelet-endothelial cell 
interactions (Gawaz, Neumann et al. 1999). An epitope present in activated 
αIIbβ3 is recognized by the antibody PAC-1, and thrombin stimulation greatly 
increased surface PAC-1 binding compared to quiescent control platelets (Figs. 
3.4 A). Pre-treating  platelets with the deubiquitinase inhibitor PYR41 for 15 min 
greatly suppressed PAC-1 binding to the extent that αIIbβ3 activation was not 
statistically distinct from unstimulated platelets (Fig. 3.4 B). The general 
deubiquitinase inhibitor PR619 also effectively reduced thrombin-stimulated 
expression of PAC-1 (Figs.3.4 E, F). Inhibition of deubiquitinase activity by either 
PYR41 (Figs. 3.4 C, D) or PR619 (Figs. G, H) also fully suppressed thrombin 
stimulation of alpha granule secretion that was detected by the translocation of 
P-selectin from alpha granules to the platelet surface. 
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Figure 3.4 Inhibitors of platelet deubiquitinases suppressed protease 
activated receptor (PAR) mediated αIIbβ3 activation and degranulation 
(A) PYR41 pretreatment suppressed stimulated αIIbβ3 activation. Flow cytometry 
using PAC-1 antibody, that binds active αIIbβ3, on platelets treated or not with 
PYR41 and with or without 0.2 U thrombin (thr, n=3). (B) Mean fluorescence 
intensity (MFI) of PAC-1 binding on platelets in panel A (n=3; *p≤ 0.05). (C) 
PYR41 pretreatment reduced P-selectin surface expression upon activation. 
Flow cytometry using PE-conjugated-anti-P-selectin antibody on platelets treated 
or not with PYR41 and with or without 0.2 U thrombin (thr, n=3). (D) Mean 
fluorescence intensity (MFI) of P-selectin binding on platelets in panel C (n=3; *p≤ 
0.05). (E)  PR619 pretreatment suppressed stimulated αIIbβ3 activation. Flow 
cytometry using PAC-1 antibody, that binds active αIIbβ3, on platelets treated or 
not with PR619 and with or without 0.2 U thrombin (thr, n=3). (F) Mean 
fluorescence intensity (MFI) of PAC-1 binding on platelets in panel E (n=3; **p≤ 
0.01). (G) PR619 pretreatment reduced P-selectin surface expression upon 
activation. Flow cytometry using PE-conjugated-anti-P-selectin antibody on 
platelets treated or not with PR619 and with or without 0.2 U thrombin (thr, n=3). 
(H) Mean fluorescence intensity (MFI) of P-selectin binding on platelets in panel 
G (n=3; **p≤ 0.01).  
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3.3.5 Inhibitors of platelet deubiquitinases suppressed ADP mediated 
αIIbβ3 activation and degranulation 
 Thrombin at the concentration used above activates platelets primarily 
through the PAR1 receptor, but activation of platelets through a second receptor, 
the P2Y12 receptor for ADP, was also abolished by deubiquitinase inhibition. 
Thus, ADP stimulation increased binding of PAC-1 to platelets (Fig. 3.5 A), 
although not to the extent induced by thrombin, and PYR41 effectively reduced 
the extent of αIIbβ3 activation after ADP activation to nearly quiescent levels 
(Fig. 3.5 B). PYR41 pretreatment also suppressed P-selectin exocytosis upon 
ADP stimulation (Fig. 3.5 C) and this reduction was statistically significant (Fig. 
3.5 D).  PR619 was equally effective in suppressing platelet integrin activation 
(Figs. 3.5 E, F).     
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Figure 3.5 Deubiquitinase inhibitors diminished ADP induced platelet 
αIIbβ3 activation and degranulation  
(A)  PYR41 pretreatment suppressed stimulated αIIbβ3 activation. Flow 
cytometry using PAC-1 antibody, that binds active αIIbβ3, on platelets treated or 
not with PYR41 and with or without 25 µM ADP (n=4). (B) Mean fluorescence 
intensity (MFI) of PAC-1 binding on platelets in panel A (n=4; **p≤ 0.01). (C) 
PYR41 pretreatment reduced P-selectin surface expression upon activation. 
Flow cytometry using PE-conjugated- anti-P-selectin antibody on platelets 
treated or not with PYR41 and with or without 25 µM ADP (n=3). (D) Mean 
fluorescence intensity (MFI) of P-selectin binding on platelets in panel C (n=3; *p≤ 
0.05). (E)  PR619 pretreatment suppressed stimulated αIIbβ3 activation. Flow 
cytometry using PAC-1 antibody, that binds active αIIbβ3, on platelets treated or 
not with PR619 and with or without 25 µM ADP (n=3). (F) Mean fluorescence 
intensity (MFI) of PAC-1 binding on platelets in panel E (n=3; *p≤ 0.05).  
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3.3.6 Proteasome associated deubiquitinases regulate platelet activation 
 A recent report using quantitative mass spectrometry shows platelets 
contain several cytoplasmic deubiquitinase enzymes including proteasome 
associated deubiquitinases USP14 and UCHL5 (Burkhart, Vaudel et al. 2012). 
USP14 and UCHL5  levels are upregulated in many cancers (D'Arcy and Linder 
2012) and thus are potential targets for anti-cancer therapies. A small molecule 
inhibitor, b-AP15, was recently identified that specifically inhibited just these two 
deubiquitinases without affecting the catalytic activities of proteasome (D'Arcy, 
Brnjic et al. 2011).  Both USP14 and UCHL5 are present  in high copy numbers 
in platelets, 3100 and 1500 copies/platelet, respectively (Burkhart, Vaudel et al. 
2012), but whether these enzymes are relevant in platelets is not known. I tested 
b-AP15 in platelets and observed ex vivo treatment of platelets with b-AP15 
leads to accumulation of high molecular weight proteins as detected by anti-
ubiquitin P4D1 antibody (Fig. 3.6 A).  
 Next I ascertained the role of proteasome associated deubiquitinases, 
USP14 and UCHL5, on platelet functions. Inhibition of these deubiquitinases with 
b-AP15, inhibited thrombin- (Fig. 3.6 B), collagen- (Fig. 3.6 C) and ADP- (Fig. 3.6 
D) induced aggregation and, like the general deubiquitinase inhibitors PYR41 
and PR619, the inhibitory effect of b-AP15 on agonist-induced platelet 
aggregation was significant (Fig. 3.6 E). b-AP15 treatment alone had no effect on 
platelet aggregation. b-AP15 pretreatment also inhibited thrombin- (Fig. 3.6 F) 
induced αIIbβ3 activation as assessed by PAC-1 binding as well as P-selectin 
exocytosis from platelet alpha-granules (Fig. 3.6 G). Activation of αIIbβ3 is critical 
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for stable thrombus formation and consolidation in vivo (Shattil and Newman 
2004; Gratacap, Guillermet-Guibert et al. 2011) and pretreatment with b-AP15 
also blocked ADP- (Fig. 3.6 H) induced αIIbβ3 activation. USP14 and UCHL5 
inhibition had a more profound inhibitory effect on collagen-induced aggregation 
(Fig. 3.6 C) than the general deubiquitinase inhibitors, so I tested the effect of 
inhibition of these enzymes on platelet adhesion to collagen under static 
conditions. b-AP15 pretreatment reduced the number of platelets adhering to a 
exposed collagen-coated surface (Fig. 3.6 I), suggesting vital role of proteasome 
associated deubiquitinases in mediating platelet interactions with bound or 
exposed collagen.  
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Figure 3.6 Pharmacologic inhibition of proteasome-associated 
deubiquitinase enzymes, USP14 and UCHL5, reduced platelet 
responsiveness to agonists   
 (A) b-AP15 pretreatment increases ubiquitination of the platelet proteome. 
Immunoblot of platelet lysates, treated or not with b-AP15, probed with anti-
ubiquitin antibody (P4D1, n=3). (B) Proteasome-associated deubiquitinases 
promote stimulated platelet aggregation. b-AP15 pretreatment inhibited thrombin-
(thr, n=3) (C) collagen- (n=3) and (D) ADP-induced aggregation (n=3). (E) b-
AP15 mediated inhibition of stimulated platelet aggregation is statistically 
significant (n=3; ***p≤ 0.001, **p≤0.01, *p≤ 0.05). (F) b-AP15 pretreatment 
suppressed stimulated αIIbβ3 activation. Flow cytometry using PAC-1 antibody, 
that binds active αIIbβ3, on platelets treated or not with b-AP15 and with or 
without  0.2 U thrombin (thr, n=3). (G) b-AP15 pretreatment reduced P-selectin 
surface expression upon activation. Flow cytometry using PE-conjugated- anti-P-
selectin antibody on platelets treated or not with b-AP15 and with or without 0.2 
U thrombin (thr, n=3). (H) Preincubation with b-AP15 suppressed ADP-induced 
αIIbβ3 activation. Flow cytometry using PAC-1 antibody, that binds active αIIbβ3, 
of platelets treated or not with b-AP15 and with or without  25 µM ADP (n=3). (I) 
Proteasome-associated deubiquitinases mediate platelet adhesion to collagen 
coated surface. Microscopic images of platelet adhesion on collagen under static 
conditions (n=2). 
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3.3.7 Platelet deubiquitinases affect collagen mediated responses via the 
gpVI receptor  
 Collagen binds and activates platelets via two major platelet surface 
receptors, α2β1 and gpVI (Nuyttens, Thijs et al. 2011). Since all three 
deubiquitinase inhibitors had a profound effect on collagen-induced aggregation, 
I next looked at the effect of these inhibitors specifically on the gpVI receptor, the 
main signaling receptor for collagen (Nieswandt and Watson 2003). Neither the 
general deubiquitinase  inhibitors, PYR41 and PR619, nor the specific 
deubiquitinase inhibitor, b-AP15, alone induced platelet aggregation (Fig. 3.7 A), 
but all three inhibitors suppressed aggregation to convulxin, a snake venom toxin 
that activates platelets via gpVI receptor (Polgar, Clemetson et al. 1997) (Fig. 3.7 
B). Convulxin stimulation increased PAC-1 binding, a marker of αIIbβ3 activation, 
but pretreatment with PYR41 (Fig. 3.7 C) or PR619 (Fig. 3.7 D) or b-AP15 (Fig. 
3.7 E) reduced convulxin induced increase in  PAC-1 binding. This suggest that 
the platelet deubiquitinases are critical for gpVI-mediated transduction of 
collagen signals.  
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Figure 3.7  Deubiquitinase inhibitors affect collagen responses via the gpVI 
receptor   
 (A) Neither general deubiquitinase inhibitors, PYR41 and PR619, nor b-AP15 
stimulated platelet aggregation in the absence of agonists. (B) Deubiquitinase 
inhibitors inhibited gpVI specific platelet responses. Platelets were pretreated 
with PYR41, PR619, or b-AP15 before initiating platelet aggregation with 
convulxin (n=2). (C) Convulxin-mediated increase in PAC-1 binding was 
assessed using flow cytometry in platelets pretreated with PYR41 (n=2), (D) 
PR619 (n=2), or  (E) b-AP15 (n=2). 
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3.3.8 Inhibition of platelet deubiquitinases modulated platelet signaling 
responses downstream of thrombin and collagen receptors 
 Akt, or protein kinase B, is a serine/ threonine kinase that is an 
established downstream effector of phosphoinositide 3-kinase (PI3K) (Bhaskar 
and Hay 2007). Platelets express two Akt isoforms, Akt1 and Akt2 (Kroner, 
Eybrechts et al. 2000; Dittrich, Birschmann et al. 2008) and targeted deletion of 
each individual isoform affects platelet function. Akt1 deletion in mice resulted in 
diminished platelet responses to thrombin and collagen (Chen, De et al. 2004; 
Stojanovic, Marjanovic et al. 2006) and Akt2 deletion suppressed platelet 
secretion and thrombosis (Woulfe, Jiang et al. 2004).  
 Platelet stimulation with thrombin resulted in time dependent increase in 
Akt phosphorylation at both ser473 and thr308 residues (Fig.3.8 A), but 
pretreatment with either general deubiquitinase inhibitors, PYR41 and PR619, or 
the specific deubiquitinase inhibitor, b-AP15, reduced thrombin-induced Akt 
activation as evident from reduced Akt phosphorlylation at both ser and thr 
residues (Fig. 3.8 A). An equivalent inhibition of collagen-induced Akt 
phosphorylation, either at ser473 or thr308, (Fig. 3.8 B) was also observed with 
all three inhibitors of deubiquitinases. The inhibition of Akt phosphorylation at 
thr308, induced by either agonist, was more profound compared to 
phosphorylation at ser473. In platelets,  Akt activation is  both PI3K dependent 
and independent, but sustained Akt activation is PI3K dependent (Jackson and 
Schoenwaelder 2010). Class IA PI3K isoform β (PI3K β) is an essential PI3K to 
promote PLCγ-2 activation downstream of gpVI-FcRγ receptor (Gratacap, 
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Guillermet-Guibert et al. 2011). PLCγ-2 activation leads to intracellular calcium 
release and DAG production and both events are critical for sustained αIIbβ3 
activation and fibrin clot retraction (Canobbio, Stefanini et al. 2009; Martin, 
Guillermet-Guibert et al. 2010). Collagen-induced intracellular calcium release 
was inhibited when platelets were preincubated with deubiquitinase inhibitors 
before stimulation by collagen (Fig.3.8 C). Deubiquitinase inhibitors also 
significantly reduced fibrin clot retraction suggesting impaired outside in signaling  
from integrin αIIbβ3 (Fig. 3.8 D).  
 Phosphatase and tensin homologue-deleted on chromosome 10 (PTEN) 
is a known negative regulator of PI3K/Akt signaling (Carracedo and Pandolfi 
2008) that regulates collagen-dependent platelet activation. Tissue specific pten 
deletion in mice resulted in increased Akt phosphorylation and platelet 
aggregation even at  much lower collagen concentrations, indicating that PTEN 
negatively regulates collagen mediated platelet activation (Weng, Li et al. 2010).  
PTEN's phosphatase activity is negatively regulated by phosphorylation at ser 
380 (Vazquez, Ramaswamy et al. 2000; Yang, Yuan et al. 2013), however this is 
not studied in platelets so far. I observed both thrombin and collagen increased 
PTEN phosphorylation at this residue (Fig. 3.8 E) and pretreatment with 
deubiquitinase inhibitors reduced agonist dependent increase in PTEN 
phosphorylation and inactivation.  
 Since deubiquitinases display linkage specificity for ubiquitin chains 
(Komander, Clague et al. 2009), I used linkage specific antibodies (K63 or K48 
specific antibodies) to determine the relative abundance of both type of linkages 
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in platelets. I observed accumulation of lysine 48 linkages (Fig. 3.8 F), but 
interestingly I did not find any accumulation of lysine 63 linkages in untreated, 
stimulated or deubiquitinase inhibitor treated platelets (not shown). An important 
role of deubiquitinases is generation of free ubiquitin pool from unanchored 
polyubiquitin chains. I observed accumulation of high molecular weight 
polyubiquitin chains upon inhibition of platelet deubiquitinases, suggesting that 
deubiquitinase enzyme mediated ubiquitin homeostasis is critical for platelet 
responses.  
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Figure 3.8 Deubiquitinase inhibitors impaired platelet signaling following 
agonist stimulation 
(A) Deubiquitinase inhibitors reduced thrombin induced Akt activation. Platelets 
treated with or without deubiquitinase inhibitors were stimulated with 0.2 U 
thrombin (thr) for the stated times and immunoblotted using anti-pAKT ser473, 
anti-pAKT thr308 or anti-Akt antibodies (n=3). (B) Deubiquitinase inhibitors 
reduced collagen-induced Akt activation. Platelets treated with or without 
deubiquitinase inhibitors were stimulated with 2 µg collagen for the stated times 
and immunoblotting was done on platelet lysates using anti-pAKT ser473, anti-
pAKT thr308 or anti-Akt antibodies (n=3).  (C) Deubiquitinase inhibitors blocked 
collagen-induced intracellular calcium release. Platelets labeled with Fura-2 AM 
were treated or not with deubiquitinase inhibitors before stimulation with 2 µg 
collagen. (D) Deubiquitinase inhibition suppressed clot retraction. Ratio of the 
image surface area of images of thrombin-induced clots over time (n=3; **p< 
0.01, *p<0.05). (E) Deubiquitinase inhibition activates PTEN. Immunoblotting of 
platelets treated or not with deubiquitinase inhibitors before stimulation with 0.2 U 
thrombin or 2 µg collagen was done using anti-phospho PTEN-ser380 antibody 
(n=2). (F) Deubiquitinase inhibition caused accumulation of lys-48 linked Ub 
conjugates. Immunoblotting of platelets treated or not with deubiquitinase 
inhibitors before stimulation with 0.2 U thrombin (thr) or 2 µg collagen was done 
using anti-K48 linked ubiquitin antibody (n=2). 
135 
 
3.5 Discussion  
 The proteome of platelets is constitutively decorated by conjugated single 
ubiquitin molecules and by ubiquitin polymeric chains, whose abundance 
increases with agonist stimulation (Gupta, Li et al. 2014). Here I present 
evidence showing that ubiquitin decoration of platelet proteins is dynamic. 
Turnover of ubiquitin decoration was elucidated by suppressing deubiquitinase 
activity by any of the general deubiquitinase inhibitors or the specific inhibitor of 
proteasome-associated deubiquitinases. This greatly increased ubiquitin protein 
modification within minutes. These changes were apparent in the absence of 
agonist stimulation, so the protein complement of quiescent platelets undergoes 
a continuous, and rapid, cycle of ubiquitination and deubiquitination. 
     Protein deubiquitination is, in fact, a critical step in unlocking platelet 
reactivity. The general deubiquitinase inhibitors PYR41 or PR619 blocked 
activation of αIIbβ3  integrin,  blocked alpha granule release and hence blocked 
the agonist-stimulated increase of surface P-selectin. These inhibitors also 
effectively blocked ex vivo homotypic platelet aggregation. The general inhibitor 
PYR41 additionally blocked formation of platelet-rich thrombi that completely 
occluded blood flow in damaged carotid arteries. I conclude the complete 
suppression of stimulated platelet function by deubiquitinase inhibition means 
that ubiquitin modification of the proteome likely maintains platelets in an inactive 
state and that deubiquitinase action may be required to release tonic ubiquitin 
inhibition. 
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 Deubiquitinase inhibitors affect platelet signaling downstream of platelet 
receptors. Thrombin and collagen induced Akt phosphorylation was reduced by 
both the pan deubiquitinase inhibitors, PYR41 and PR619, and the specific 
inhibitor of proteasome associated deubiquitinase activity, b-Ap15.  Akt activation 
in platelets is both PI3K-dependent and PI3K-independent (Laurent, Severin et 
al. 2014), however, class IA PI3K isoform β (PI3K β) is mandatory for gpVI-FcRγ 
receptor-mediated Akt activation, platelet aggregation, intracellular calcium 
release and degranulation (Kim, Mangin et al. 2009). I attribute these effects  to 
the upregulation of PTEN activity upon pretreatment with deubiquitinase 
inhibitors. PTEN negatively regulates Akt activation by converting 
phosphatidyinositol 3,4,5-trisphosphate (PIP3) to phosphatidylinositol 4,5-
bisphosphate (PIP2) and its been reported to negatively regulate collagen-
induced platelet activation (Weng, Li et al. 2010). Deubiquitinase inhibitors also 
significantly reduced clot retraction over time, indicating impaired outside-in 
integrin signaling. Phosphoinositide-dependent protein kinase 1 (PDK1) is 
activated upon an increase in PIP3 following PI3K activation and activated PDK1 
phosphorylates Akt at residue thr308 (Moore, Hunter et al. 2011). Platelet 
specific knockdown of PDK1 and subsequent loss in Akt phosphorylation 
reduced thrombin-induced platelet aggregation, clot retraction and thrombosis 
(Chen, Zhang et al. 2013).  
 Activation of PI3K and its effector, Akt, is essential for most aspects of 
collagen-induced platelet activation, and thrombin- and collagen-induced αIIbβ3 
integrin outside-in signaling. The effect of PI3K/Akt axis on thrombin-induced 
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aggregation is only seen at low thrombin concentrations and is overcome at high 
agonist concentrations (Martin, Guillermet-Guibert et al. 2010; Chen, Zhang et al. 
2013). Additionally, the effect of thrombin-induced aggregation can be reversed 
using P2Y12 inhibitors, suggesting it's not a direct effect but is due to thrombin-
induced platelet ADP secretion (Kim, Mangin et al. 2009). However, it is 
controversial because P2Y12 knockout mice showed Akt phosphorylation in 
response to thrombin, indicating a direct effect. In the same study it was shown 
that the Src family of kinases (SFKs) act upstream of PI3K/Akt axis. The 
discrepancy was attributed to nonspecific effects of P2Y12 inhibitors used in the 
first study (Xiang, Zhang et al. 2010). I recognize the fact that the strong effect of 
pan deubiquitinase inhibitors, PYR41 and PR619, on thrombin-induced 
aggregation is independent of Akt activation, but I have seen a reduction in 
thrombin induced intracellular calcium release after pretreatment with pan 
deubiquitinase inhibitors (not shown) as I found when collagen was the agonist. 
This did not occur with b-AP15, which also explains the strong effect of pan 
deubiquitinase inhibitors and mild effect of b-AP15 on thrombin induced 
aggregation.  
 Furthermore, I have not identified a direct target that is modulated by 
deubiquitinase inhibition and that needs further experimentation. However, there 
could be another possibility for the switch in platelet responsiveness since it is 
notable that quiescent platelets lacked free ubiquitin monomer. Also the anti-
ubiquitin-active band with the most rapid mobility during SDS-PAGE is ~ 17 kDa 
(Fig. 3.1 D), which is consistent with the anticipated mobility of di-ubiquitin. I have 
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not lost monomeric 8 kDa ubiquitin from my gels of platelet lysates since I detect 
recombinant monomeric ubiquitin. Moreover, I observed accumulation of only 
K48-linked substrates upon pretreatment with deubiquitinase inhibitors (Fig. 3.8 
F), but this is not due to proteasome inhibition as none of the three inhibitors 
inhibited the proteasome catalytic activity (Altun, Kramer et al. 2011; D'Arcy, 
Brnjic et al. 2011; Kapuria, Peterson et al. 2011) that also results in K48-
polyubiquitination of the platelet proteome (Gupta, Li et al. 2014). So, it is 
possible that all platelet ubiquitin is either fully adducted with protein or exists as 
unanchored polymeric ubiquitin chains (Strachan, Roach et al. 2012). 
Quantitative mass spectrometry reports 3600 copies of polyubiquitin B per 
platelet, the trimeric ubiquitin precursor, but no free monomer (Burkhart, Vaudel 
et al. 2012). Instead, I propose monomeric platelet ubiquitin would not be present 
or available to conjugate to new protein targets until ubiquitin sequestered in 
either protein or unanchored ubiquitin chains is first released by deubiquitinase 
action. This could mean the essential role of deubiqutination in platelet activation 
is either to release ubiquitin from existing depots that would allow its conjugation 
to a new target protein, or the relevant change could be a required remodeling of 
existing polyubiquitin chains. 
 The deubiquitinase inhibitors b-AP15 and PR619 strongly suppressed 
stimulated platelet function ex vivo, and I suggest the effect of PYR41 similarly 
was through inhibition of deubiquitinase activity. This compound was identified as 
an inhibitor of ubiquitin E1 activity (Yang, Kitagaki et al. 2007), although it was 
effective in suppressing E1 activity in vitro (not shown). However, it did not 
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interfere with ubiquitin activation in platelets and, like b-Ap15 and PR619, PYR41 
caused a rapid and massive increase in ubiquitin decoration of soluble platelet 
proteins. This is incompatible with E1 inhibition, which could indicate ubiquitin 
activation through the second E1 enzyme except that this protein was not 
discovered in the platelet proteome (Burkhart, Vaudel et al. 2012). However, 
PYR41 is routinely used as an  E1 inhibitor as evident from several publications 
and it is recently shown that PYR41 at 25 µM concentration blocked cyclophilin A 
dependent ubiquitination of CXCR7. This is induced by SDF-1α and its a 
prerequisite for the surface externalization of CXCR7 in platelets (Chatterjee, 
Seizer et al. 2014). Although I observed a strong  inhibitory effect of PYR41 on 
platelet deubiquitinases, I have not discounted the possibility that PYR41 might 
act as a dual inhibitor of both E1 activity and deubiquitinase activity. I therefore 
performed parallel to the PYR41, experiments with general deubiquitinase 
inhibitor, PR619, and specific deubiquitinase inhibitor, b-AP15, and I show that 
compounds inhibiting a range of deubiquitase family members suppressed 
platelet function. 
 Taken together, I have identified a new pathway that regulates platelet 
function. I have identified that platelets contain several deubiquitinases and both 
the  general deubiquitinase inhibitors as well as specific inhibitor of proteasome- 
associated deubiquitinases modulate platelet reactivity to various agonists. 
Inhibition of platelet deubiquitinases suppressed platelet aggregation, secretion 
and adhesion of isolated platelets in response to all agonists. Additionally, 
systemic blockade of deubiquitination also reduced arterial thrombosis in FeCl3-
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damaged carotid arteries. I also show that the deubiquitinase inhibitors, PYR41, 
PR619, and b-AP15, affect downstream signaling from the collagen receptor, as 
evident from reduced Akt activation, likely via upregulation of PTEN activity. This 
is the first report that establishes agonist-dependent regulation of PTEN activity 
in platelets. Platelet deubiquitinases are critical for platelet responsiveness and 
the specific inhibitor of proteasome associate deubiquitinases, b-AP15, is already 
in active preclinical trials. This strongly makes the case that platelet 
deubiquitinases can be a new class of anti-thrombotic drug targets.  
3.6 Chapter summary 
 These data further show that platelet ubiquitin-proteasome pathway is 
crucial in modulating platelet reactivity. I show that ubiquitination of platelet 
proteins is dynamic, platelets express several deubiquitinases, and platelet 
deubiquitinases are functional. Specific inhibition of the proteasome-associated 
deubiquitinases (b-AP15) as well as pan deubiquitinase inhibitors (PYR41 and 
PR619) increased mono- and poly-ubiquitination of platelet proteins. These 
agents also blocked platelet degranulation upon stimulation. Deubiquitinase 
inhibition suppressed αIIbβ3 activation, platelet aggregation, and adhesion/ 
spreading in response to diverse platelet agonists. Inhibition of platelet 
deubiquitinase activity strongly suppressed formation of platelet-rich occlusive 
thrombi in FeCl3-damaged murine carotid arteries and inhibition of platelet 
deubiquitinase activity prevented in vitro thrombus formation on collagen-coated 
surfaces at high shear rates. These inhibitors also blocked downstream signaling 
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from platelet receptors by inhibiting agonist-induced Akt phosphorylation 
associated with upregulation of PTEN activity. This is the first report that 
established agonist-dependent regulation of PTEN activity in platelets. These 
data uncovers a new mechanism that maintains circulating platelets in a 
quiescent state.  
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Chapter IV 
Ubiquitin-specific protease 7 (USP7) activity promotes platelet activation 
4.1 Introduction and Rationale 
 Arterial thrombotic occlusion causes myocardial infarction and ischemic 
stroke and is the single most common cause of death and disability in the 
developed world (Sanz, Moreno et al. 2012). Platelets play central roles in the 
development of arterial thrombosis and are therefore the main target of anti-
thrombotic therapies. Current anti-platelet therapies, most commonly aspirin 
and/or clopidogrel, are not fully effective in the prevention of arterial thrombosis, 
and novel anti-platelet agents are therefore sought (Meadows and Bhatt 2007; 
Michelson 2011). We have previously demonstrated that platelets contain a 
functional ubiquitin-proteasome system, that proteasome mediated proteolysis is 
required both for ex vivo platelet activation and for in vivo development of arterial 
thrombosis (Gupta, Li et al. 2014). We have also recently established that, like 
nucleated cells, the ubiquitination of platelet proteins is dynamic, so platelet 
deubiquitinases that catalyze this turn-over are functional and modulate platelet 
reactivity (unpublished).  
 Targeting ubiquitin-proteasome system in platelets seems promising, and 
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small molecule inhibitors targeting specific and smaller portions of ubiquitin-
proteasome pathway have shown encouraging results in other settings targeting 
USP7 in nucleated cells.  A recent quantitative mass spectrometry shows 
platelets express deubiquitinase USP7 (ubiquitin-specific protease 7 or 
Herpesvirus-associated ubiquitin-specific protease, HAUSP). This is interesting 
as USP7 participates in the control of the cell cycle, which is irrelevant to 
platelets, but quantitative mass spectrometry shows platelets contain 1300 
copies of USP7 peptides per platelet (Burkhart, Vaudel et al. 2012). 
USP7/HAUSP modulates proteins involved in cell cycle regulation, as well as 
oncogenes and tumor suppressors and is therefore a  strategic target for cancer 
therapy (Reverdy, Conrath et al. 2012). USP7/HAUSP inhibitors are already in 
active preclinical development owing to their role in p53 regulation (Shen, 
Schmitt et al. 2013). These inhibitors induce apoptosis of tumor cells (Reverdy, 
Conrath et al. 2012) and apoptosis of multiple myeloma cells that have overcome 
resistance to the proteasome inhibitor bortezomib (Chauhan, Tian et al. 2012). 
 USP7/HAUSP is abundant in platelets and we have observed (chapter III, 
Fig. 3.1 B) reduction in the intensity of the protein band at ~ 130 kD, which 
corresponds to the molecular weight of USP7/HAUSP, after treatment with 
generic deubiquitinase inhibitors. Whether USP7/HAUSP modulates platelet 
reactivity has not been studied. Here I show that specific inhibition of 
USP7/HAUSP suppresses platelet aggregation in response to collagen and 
adhesion under flow. This study indentifies USP7/HAUSP inhibition as a potential 
new approach to anti-platelet therapy. 
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4.2 Results 
4.2.1 USP7/HAUSP activity promotes platelet activation  
 Active deubiquitinase enzymes are specifically covalently adducted during 
hydrolysis of the suicide substrate, HA-tagged ubiquitin-vinyl sulfone 
(Borodovsky, Kessler et al. 2001), and we used this approach to determine 
whether platelets have active USP7/HAUSP. Platelets treated with either pan 
DUB inhibitors (PYR41 and PR619) or structurally unrelated USP7/HAUSP 
inhibitors (HBX 41108 and P22077)  were incubated with HA-ubiquitin-vinyl 
sulfone. Immunoprecipitation with anti-HA antibody was used to enrich active 
deubiquitinases. Immunoblotting with anti-HAUSP antibody confirmed the 
presence of active USP7/HAUSP in platelets as a full length 130 kDa protein, 
and I found that its activity was suppressed by the general inhibitors PYR41 and 
PR619 (Fig. 4.1 A).Selective small molecule inhibitors of USP7/HAUSP, HBX 
41108 and P22077, were equally effective or better in blocking deubiquitination 
by this enzyme (Fig. 4.1 B). 
     Selective USP7/HAUSP inhibition by HBX 41108 abolished platelet deposition 
from whole blood onto the collagen-coated surface of a microfluidic channel 
during flow at high shear (Fig. 4.1 C) and this inhibition was significant (Fig. 4.1 
D). Neither HBX 41108 nor P22077 alone induced platelet aggregation (Fig. 4.1 
E), but each inhibitor suppressed collagen induced platelet aggregation in 
purified platelet preparations (Fig. 4.1 F). This inhibition was significant, and 
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equivalent (Fig. 4.1 G). 
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Figure 4.1 USP7/HAUSP inhibition blocked collagen-stimulated aggregation 
and adhesion under flow 
(A) Platelets contain active USP7/HAUSP. Western blot of anti-HA 
immunoprecipitates with anti-HAUSP antibody after active-site–directed labeling 
of deubiquitinases with HA- tagged Ubiquitin-Vinyl sulfone (HA-UbVS) in platelet 
lysates from washed platelets pre-treated with or without PYR41 or PR619 for 30 
min (n=3). (B) Western blot of anti-HA immunoprecipitates with anti-HAUSP 
antibody after active-site–directed labeling of deubiquitinases with HA- tagged 
UbVS in platelet lysates from washed platelets pre-treated with or without HBX 
41108 (30 µM) or P22077 (30 µM) for 30 min (n=3). (C) USP7/HAUSP inhibition 
by HBX 41108  blocked platelet adhesion to collagen at high shear. Calcein-AM 
labeled blood, treated or not with HBX 41108 (30 µM) for 30 min, was perfused 
over immobilized type 1 collagen fibrils (150 µg/ml) at 67.5 dyne/cm2 for 3 min. 
Images are representative fields taken after 3 min from three independent 
experiments that yielded similar results (n=3). (D) Area of platelet attachment 
after HBX 41108 treatment. Platelet area in panel C was quantified by ImagePro 
plus software and results are plotted as area of platelet adhesion in square 
microns (n=3; ***p≤ 0.001). (E) Neither HBX 41108 (30 µM) or P22077 (30 µM) 
stimulated platelet aggregation in the absence of agonists. (F) HBX 41108 (30 
µM) or P22077 (30 µM) pretreatment for 30 min blocked collagen-induced 
aggregation (3 µg/ml). (E) HBX 41108 or P22077 imposed reduction in collagen-
induced aggregation was statistically significant (n=3; ***p≤ 0.001). 
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4.3 Chapter summary 
 These data confirm that components of the platelet ubiquitin-proteasome 
system are potential anti-thrombotic targets. I show inhibition of a specific 
deubiquitinase, USP7/HAUSP, strongly suppressed formation of platelet-rich 
thrombi that formed on collagen-coated surfaces at high shear rates and 
suppressed platelet aggregation in response to collagen.  The deubiquitinase 
family contains nearly 100 members that accept a range of monomeric and 
polymeric ubiquitin-conjugated protein substrates, and the polymeric ubiquitin 
chains themselves are polydisperse from varied polymer length and branching 
from the seven lysine residues of ubiquitin that are sites of polymerization 
(Nijman, Luna-Vargas et al. 2005). Deubiquitinases, thus, generally show broadly 
overlapping substrate specificities. 
USP7/HAUSP, member of the DUB family, in contrast, is selective and 
recognizes ubiquitinated p53 and MDM2, with a critical role in cell cycle 
regulation (Hu, Gu et al. 2006; Faesen, Dirac et al. 2011). Participation of 
USP7/HAUSP in deubiquitinating both p53 and its MDM2 E3 ligase, and its 
participation in the cell cycle, suggests therapeutic opportunities in inhibiting 
USP7/HAUSP in cancer biology (Colland, Formstecher et al. 2009; Nicholson 
and Suresh Kumar 2011). This has led to the development of potent and 
selective USP7/HAUSP inhibitors (Reverdy, Conrath et al. 2012).  
149 
 
 In this study, I find two specific inhibitors of USP7/HAUSP that blocked 
platelet aggregation by collagen and platelet adhesion under flow. Inhibition or 
loss of collagen receptor, gpVI, prevented arterial thrombosis in animal models 
without affecting normal hemostasis in both mice and humans (Kahn 2004), 
making gpVI a suitable therapeutic target. These data define a focused role for 
this deubiquitinase in response to just collagen. This shows USP7/HAUSP is 
required for successful platelet interaction with collagen fibrils exposed in 
damaged vessels, but does not then participate in platelet activation by soluble 
agonists. This strongly makes the case that platelet USP7/HAUSP can be a new 
class of anti-thrombotic drug target that specifically dampens platelet 
responsiveness to collagen. 
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Chapter V 
Conclusion  
5.1 Summary and Conclusion 
 Overall, the studies presented in this thesis provide evidence that the 
ubiquitin-proteasome system is an important regulator of platelet responsiveness 
to diverse stimuli. Pharmacologic inhibitors against specific components of UPS 
(Fig. 5.1) were used to determine the individual effect of selective inhibition of 
these components on platelet function. Proteasome inhibition modulated platelet 
aggregation, spreading, microparticle shedding, clot retraction, thrombus 
formation and thrombus stability. The requirement for platelet deubiquitinase 
activity in platelet responses varied among platelet agonists. Specific 
deubiquitinase inhibitors, as well as general deubiquitinase inhibitors, 
suppressed stimulated platelet aggregation, adhesion/spreading, platelet 
degranulation, αIIbβ3 activation and outside-in signaling from αIIbβ3. Systemic 
blockade of deubiquitination also reduced arterial thrombosis in FeCl3-damaged 
carotid arteries. The inhibition of proteasome-associated deubiquitinases or 
soluble deubiquitinase USP7/HAUSP, showed that the platelet responses 
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downstream of the collagen receptor were dampened. However, since pan 
deubiquitinase inhibitors block stimulation by all major agonists, there are 
receptor-specific as well as receptor-non-specific processes that depend on 
deubiquitination.  
 To conclude, this study has identified a novel pathway that regulates 
platelet function and reactivity. Further understanding of the mechanisms that 
regulate this pathway in platelets and characterization of specific proteins that 
are being modulated by this pathway seems vital for the development of new and 
improved anti-platelet therapies.  
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Figure 5.1 Pharmacologic inhibition of different components of UPS 
modulates platelet reactivity 
(A) Proteasome inhibitors MG132 and bortezomib inhibit the catalytic activities of 
the proteasome. (B) PYR41 and PR619 are two structurally unrelated pan DUB 
inhibitors that inhibit both soluble DUBs as well as proteasome associated DUBs 
i.e USP14 and UCHL5. (C) b-AP15 is a specific and selective inhibitor of 
proteasome associated DUBs i.e USP14 and UCHL5. (D) HBX 41108 and 
P22077 are irreversible inhibitors of USP7/HAUSP. 
A 
B 
C 
D 
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